- Published on
Infectious Disease – Diarrhea and Fever
FUNDAMENTALS AND DESCRIPTION
Diarrhea is clinically defined as an elevation in daily stool weight above 200 grams and more broadly characterized as the occurrence of three or more loose stools daily. Diarrhea is classified as acute when it persists for less than 14 days and as chronic when it endures for more than 4 weeks. An inflammatory diarrheal syndrome is defined by frequent, small-volume feces that may be mucoid, bloody, or both. It may be associated with tenesmus, fever, or intense stomach pain. The defining characteristic of inflammatory diarrheas is the presence of leukocytes in the feces. A noninflammatory diarrheal condition is defined by the presence of voluminous watery stools (>1 L/d) that lack blood, pus, significant abdominal pain, or fever.
Epidemiology: Incidence Approximately 200 to 375 million instances of severe diarrhea transpire annually in the United States. Approximately 38 million of these events are ascribed to a recognized pathogen (bacteria, parasite, or virus). Foodborne transmission is responsible for approximately 36% of diarrheal diseases caused by identified pathogens. In 2007, of the 9 bacterial enteropathogens monitored by FoodNet, the predominant causes were non-typhoid salmonella (14.86 cases per 100,000 population), campylobacter (12.78), shigella (6.24), cryptosporidium (2.67), and Shiga toxin-producing E. coli (STEC) O157 (1.19). • The prevalence of bacterial diarrhea attributed to salmonella, campylobacter, and yersinia is greatest in infants under one year of age. The prevalence of post-diarrheal hemolytic uremic syndrome (HUS) in the United States is 0.65 instances per 100,000 individuals, with the highest frequency observed in children under five years of age. • Traveler's diarrhea impacts 20–60% of global travelers.
RISK FACTORS • Ingesting uncooked eggs, pork, shellfish, poultry, or unpasteurized dairy products. • Consuming unpurified water from streams or rivers. Conditions linked to heightened illness severity or increased susceptibility to specific pathogens encompass HIV infection, immunosuppressive therapies (such as glucocorticoids, TNF inhibitors, and chemotherapy), recent antibiotic administration, hepatic disease, neutropenia, malnutrition, zinc deficiency, and IgA deficiency. • Oral-anal sexual intercourse • Antibiotic exposure is a risk factor for C. difficile-associated diarrhea.
GENERAL PREVENTION
• Cleanse hands with soap prior to consuming or preparing food. • Refrain from ingesting raw or undercooked eggs, poultry, meat, fish, and seafood. • Avoid unpasteurized dairy products. • Do not consume untreated stream or river water. • When traveling, eschew tap water and ice in regions with potentially contaminated water. • Vaccines are accessible to prevent Salmonella typhi related to international travel. Refer to the CDC website for recommended immunizations according to your destination (http://www.cdc.gov/). The Advisory Committee on Immunization Practices recommends the rotavirus vaccine for infants in the United States. CAUSES Bacteria include Campylobacter, Salmonella species, E. coli (a. Enterotoxigenic [ETEC], b. Enteropathogenic [EPEC], c. Enteroinvasive [EIEC], d. Shiga toxin-producing [STEC] including E. coli O157:H7, and e. Enteroaggregative [EAEC]), Shigella species, Yersinia enterocolitica, Clostridium difficile, Vibrio cholera, Vibrio parahaemolyticus, Aeromonas species, and Plesiomonas shigelloides. • Viruses (Rotavirus, human caliciviruses including noroviruses, Adenovirus, and Cytomegalovirus) • Parasites (Giardia intestinalis, Cryptosporidium parvum, Entamoeba histolytica, Cyclospora cayetanensis, Isospora belli, and Strongyloides stercoralis) • Toxin-mediated diarrhea (Staphylococcus aureus, Bacillus cereus, and Clostridium perfringens)
DIAGNOSIS HISTORY
A comprehensive medical history and physical examination are crucial for identifying the potential cause, severity, and existence of problems. • Inquire about recent travel, dietary habits, antibiotic consumption, sexual activity, attendance at day-care facilities, other illnesses, outbreaks, and seasonal factors. • Ascertain the frequency, duration, and nature of diarrhea (e.g., watery, bloody, etc.). • Infectious diarrhea may be accompanied by fever, chills, vomiting, nausea, stomach discomfort, and tenesmus. A history of dizziness, syncope, or presyncope suggests volume depletion. Bloody stools (dysentery) indicate the presence of an invasive infection, including Shigella, Salmonella, Campylobacter, Shiga toxin-producing E. coli (notably in the absence of fever), or Yersinia. Shiga toxin-producing E. coli, particularly O157:H7, induces watery diarrhea that progresses to bloody diarrhea and is linked to the consumption of contaminated beef or produce in around fifty percent of cases. Fever is frequently absent. Yersinia and Salmonella can infect the terminal ileum and cecum, presenting with right lower quadrant pain and tenderness indicative of acute appendicitis. • Watery diarrhea is clinically ambiguous. Gastroenteritis resulting from an enterotoxin (food poisoning) may be attributed to S. aureus, B. cereus, or C. perfringens. These instances may manifest with isolated vomiting (S. aureus or C. perfringens) or watery diarrhea (B. cereus or C. perfringens). Fever is typically absent. The incubation period is brief (2–7 hours for S. aureus; 8–14 hours for C. perfringens; C. perfringens may exhibit either duration) and the overall duration is limited. Extraintestinal signs, like arthritis, dermatological diseases, or eye problems, indicate the presence of inflammatory bowel disease. • The cause of recent overseas travel is contingent upon the place, environment, and season. The predominant pathogens comprise enterotoxigenic E. coli, enteroaggregative E. coli, Campylobacter, Salmonella, and norovirus. The CDC Travelers' Health website or other travel medicine resources can assist in diagnostic evaluation.
PHYSICAL EXAMINATION • Evaluate blood pressure, heart rate, respiration rate, temperature, and mental status to determine the severity. • Assess for indicators of dehydration such as xerostomia, impaired skin turgor, enophthalmos, reduced capillary refill time, low jugular venous pressure, or orthostatic hypotension. • Examine for abdominal discomfort, manifestations of peritonitis (guarding, rebound tenderness), hepatomegaly, and splenomegaly.
DIAGNOSTIC TESTS AND INTERPRETATION
Laboratory Initial Assessments
• The indications for diagnostic testing encompass the following: Fever, systemic sickness, hematochezia, dehydration, a confirmed or suspected outbreak of foodborne illness, recent international travel, immunosuppression, or recent antibiotic administration. Submit stool specimen for culture analysis. In the majority of microbiology laboratories, stool samples submitted for the culture of enteric pathogens will be analyzed for Shigella, Salmonella, and Campylobacter. Consequently, if there is a strong clinical suspicion for E. coli (STEC, ETEC, EPEC, EIEC), Yersinia, Vibrio, etc., inform the microbiology laboratory. The diagnostic yield of stool cultures varies between 1.5% and 5.6%. • In cases with bloody diarrhea, do stool cultures for Salmonella, Shigella, Campylobacter, and Shiga toxin-producing E. coli, and conduct an immunoassay for Shiga toxin. Upon isolation of E. coli, dispatch to a reference laboratory for serotyping. • In cases of recent antibiotic use, hospitalization, daycare exposure, or chemotherapy, stool specimens should be analyzed for C. difficile toxins A and B. For diarrhea lasting over 7 days, collect numerous stool specimens for ova and parasite analysis, specifically targeting Giardia, Cryptosporidium, Isospora belli, and Cyclospora. Evaluate noninfectious etiology. In individuals with AIDS or immunosuppression, further test for microsporidia, Mycobacterium avium.
complex, and CMV. • A positive fecal test for polymorphonuclear cells indicates inflammatory diarrhea. Subsequent Actions & Unique Considerations In cases of dehydration or severe sickness, assess serum electrolytes, renal function, hepatic function, total blood count, and blood cultures. Imaging If the diagnosis is ambiguous, accompanied by critical illness, significant abdominal pain, or signs of peritonitis, consider performing a CT scan with both oral and intravenous contrast. Diagnostic Procedures and Additional Methods For additional assessment, contemplate upper gastrointestinal endoscopy or colonoscopy accompanied by diagnostic biopsies.
DIFFERENTIAL DIAGNOSIS • Acute inflammatory diarrheal syndrome may also arise from noninfectious causes, including ulcerative colitis, Crohn’s disease, radiation or ischemic colitis, partial bowel obstruction, diverticulitis, laxative abuse, rectosigmoid abscess, Whipple’s disease, pernicious anemia, diabetes, malabsorption, scleroderma, or celiac sprue. Diarrhea and fever may also arise from infections beyond the gastrointestinal tract, such as malaria or sepsis.
THERAPY PHARMACEUTICALS
The major elements of treatment consist of fluids and antibiotics. Oral rehydration constitutes the most suitable and cost-effective management strategy for both developing and wealthy nations. Intravenous volume repletion is warranted in cases of severe dehydration or significant electrolyte imbalance. The rice-based oral solution is more effective in adults and children suffering from cholera. Antimicrobial therapy is warranted in cases of severe infection and is advised for persistent gastroenteritis, individuals over 65 years of age, immunocompromised patients, those with prosthetic devices, and in instances of invasive infections, excluding those caused by Shiga toxin-producing E. coli. Empiric therapy: For febrile community-acquired invasive diarrhea or moderate to severe traveler's diarrhea, administer ciprofloxacin 500 mg twice day or levofloxacin 500 mg daily while awaiting stool investigations, unless Shiga toxin-producing E. coli is suspected. In the event of recent travel to Southeast Asia, investigate fluoroquinolone-resistant Campylobacter. If there has been recent antibiotic usage or nosocomial diarrhea, administer metronidazole or vancomycin while awaiting assay results for C. difficile toxin.
Chosen pathogens and their treatment: • Salmonella (non-typhi species) — Bacteremia manifests in 2–8% of cases. Administer treatment for severe disease in individuals under 12 months, over 50 years, with valvular disease, severe atherosclerosis, prosthetic devices, cancer, HIV, uremia, sickle cell disease, and other immunocompromised conditions. Ciprofloxacin 500 mg orally twice daily or levofloxacin 500 mg orally once daily for 5 to 7 days. If susceptible, provide TMP-SMX DS twice daily for 5–7 days, or ceftriaxone 2 g IV/IM daily for 5–7 days. Administer treatment for 14 days if the individual is immunocompromised. Antibiotics may augment shedding. • Shigellosis – provide ciprofloxacin 500 mg orally twice daily, or levofloxacin 500 mg once daily for 3 days, or if susceptible, TMP-SMX DS twice daily for 3 days. Administer treatment for 7 to 10 days in cases of severe disease or in immunocompromised individuals. • Campylobacter – provide erythromycin 500 mg bi-daily for a duration of 5 days. Significant fluoroquinolone resistance, particularly in Southeast Asia. • Escherichia coli, Shiga toxin-producing (STEC) – Avoid antibiotics as they may elevate the risk of hemolytic uremic syndrome (HUS).
Auxiliary care. • E. coli (ETEC, EPEC, EIEC) – provide ciprofloxacin 500 mg orally twice daily or levofloxacin 500 mg daily for a duration of 3 days. Administer TMP-SMX DS bi-daily for three days if susceptible. • Yersinia – antibiotics are generally unnecessary. For severe infections or immunocompromised patients, administer doxycycline in conjunction with an aminoglycoside, fluoroquinolone, or TMP-SMX. • C. difficile – discontinue superfluous antibiotics and use metronidazole 500 mg three times daily for moderate cases or vancomycin 125 mg four times daily for 10–14 days. Kindly refer to the pertinent subject. • Cholera: Fluid replenishment is essential. Examine local susceptibilities. Treatment options include doxycycline, tetracycline, TMP-SMX, or fluoroquinolone. Amebiasis: Administer metronidazole 750 mg three times daily for five days (ten days in severe cases), followed by paromomycin 500 mg three times daily for seven days, or iodoquinol 650 mg three times daily for twenty days. • Giardiasis: Metronidazole 250–750 mg administered thrice day for 7–10 days or tinidazole 2 g as a single dose • Cyclospora & Isospora – Administer TMP-SMX 1 DS bi-daily for a duration of 7–10 days. If immunocompromised, prolong treatment and contemplate suppression.
SUPPLEMENTARY THERAPY
Comprehensive Strategies • The majority of mild instances are self-resolving. Symptomatic treatment encompasses water and anti-motility medicines, including loperamide. Loperamide is the preferred antidiarrheal medication for people experiencing mild to moderate diarrhea without hematochezia. It is contraindicated in instances of severe inflammatory or bloody diarrhea, C. difficile infection, and in children under 2 years of age. Bismuth salicylate functions as an antisecretory agent and can diminish stool output in both children and adults. Concerns for Referral • In instances of severe or persistent diarrhea of indeterminate origin, consider consulting gastroenterology and/or infectious diseases specialists. • Document instances of Salmonella species, Shigella, Campylobacter, E. coli, cholera, cryptosporidiosis, cyclosporiasis, Vibrio species, and any suspected or confirmed outbreaks.
INPATIENT CONSIDERATIONS
Preliminary Stabilization Immediate rehydration and empirical antibiotics are necessary in cases of severe acute diarrhea accompanied by systemic toxicity. Criteria for Admission Admit individuals exhibiting severe dehydration or an inability to sustain fluid intake. Intravenous Fluids Intravenous volume repletion is warranted in cases of severe dehydration or when the patient exhibits changed mental status. Criteria for Discharge Patients may be discharged after fevers diminish for over 24 hours, vital signs stabilize, and the patient can sustain sufficient fluid and food intake.
CONTINUED MANAGEMENT POST-TREATMENT SUGGESTIONS
Evaluate and administer treatment to families exhibiting like symptoms.
DIET • Nutritional intake may commence four hours following the initiation of oral or intravenous hydration. • Provide regular, little portions of easily digestible food. Avoid hyperosmolar fruit juices, as they may worsen diarrhea.
INFORMATION FOR PATIENTS
Instruct patients on general food safety practices and methods to prevent foodborne infections, particularly during travel. OUTLOOK Gastrointestinal diseases account for about 900,000 hospitalizations and 6,000 fatalities in the United States each year.
COMPLICATIONS
Complications encompass dehydration, electrolyte imbalances, bacteremia and sepsis, malnutrition and vitamin deficiency, hemolytic uremic syndrome (HUS), and systemic amebiasis.
FUNDAMENTALS AND DESCRIPTION
Diarrhea is clinically defined as an elevation in daily stool weight above 200 grams and more broadly characterized as the occurrence of three or more loose stools daily. Diarrhea is classified as acute when it persists for less than 14 days and as chronic when it endures for more than 4 weeks. An inflammatory diarrheal syndrome is defined by frequent, small-volume feces that may be mucoid, bloody, or both. It may be associated with tenesmus, fever, or intense stomach pain. The defining characteristic of inflammatory diarrheas is the presence of leukocytes in the feces. A noninflammatory diarrheal condition is defined by the presence of voluminous watery stools (>1 L/d) that lack blood, pus, significant abdominal pain, or fever.
Epidemiology: Incidence Approximately 200 to 375 million instances of severe diarrhea transpire annually in the United States. Approximately 38 million of these events are ascribed to a recognized pathogen (bacteria, parasite, or virus). Foodborne transmission is responsible for approximately 36% of diarrheal diseases caused by identified pathogens. In 2007, of the 9 bacterial enteropathogens monitored by FoodNet, the predominant causes were non-typhoid salmonella (14.86 cases per 100,000 population), campylobacter (12.78), shigella (6.24), cryptosporidium (2.67), and Shiga toxin-producing E. coli (STEC) O157 (1.19). • The prevalence of bacterial diarrhea attributed to salmonella, campylobacter, and yersinia is greatest in infants under one year of age. The prevalence of post-diarrheal hemolytic uremic syndrome (HUS) in the United States is 0.65 instances per 100,000 individuals, with the highest frequency observed in children under five years of age. • Traveler's diarrhea impacts 20–60% of global travelers.
RISK FACTORS • Ingesting uncooked eggs, pork, shellfish, poultry, or unpasteurized dairy products. • Consuming unpurified water from streams or rivers. Conditions linked to heightened illness severity or increased susceptibility to specific pathogens encompass HIV infection, immunosuppressive therapies (such as glucocorticoids, TNF inhibitors, and chemotherapy), recent antibiotic administration, hepatic disease, neutropenia, malnutrition, zinc deficiency, and IgA deficiency. • Oral-anal sexual intercourse • Antibiotic exposure is a risk factor for C. difficile-associated diarrhea.
GENERAL PREVENTION
• Cleanse hands with soap prior to consuming or preparing food. • Refrain from ingesting raw or undercooked eggs, poultry, meat, fish, and seafood. • Avoid unpasteurized dairy products. • Do not consume untreated stream or river water. • When traveling, eschew tap water and ice in regions with potentially contaminated water. • Vaccines are accessible to prevent Salmonella typhi related to international travel. Refer to the CDC website for recommended immunizations according to your destination (http://www.cdc.gov/). The Advisory Committee on Immunization Practices recommends the rotavirus vaccine for infants in the United States. CAUSES Bacteria include Campylobacter, Salmonella species, E. coli (a. Enterotoxigenic [ETEC], b. Enteropathogenic [EPEC], c. Enteroinvasive [EIEC], d. Shiga toxin-producing [STEC] including E. coli O157:H7, and e. Enteroaggregative [EAEC]), Shigella species, Yersinia enterocolitica, Clostridium difficile, Vibrio cholera, Vibrio parahaemolyticus, Aeromonas species, and Plesiomonas shigelloides. • Viruses (Rotavirus, human caliciviruses including noroviruses, Adenovirus, and Cytomegalovirus) • Parasites (Giardia intestinalis, Cryptosporidium parvum, Entamoeba histolytica, Cyclospora cayetanensis, Isospora belli, and Strongyloides stercoralis) • Toxin-mediated diarrhea (Staphylococcus aureus, Bacillus cereus, and Clostridium perfringens)
DIAGNOSIS HISTORY
A comprehensive medical history and physical examination are crucial for identifying the potential cause, severity, and existence of problems. • Inquire about recent travel, dietary habits, antibiotic consumption, sexual activity, attendance at day-care facilities, other illnesses, outbreaks, and seasonal factors. • Ascertain the frequency, duration, and nature of diarrhea (e.g., watery, bloody, etc.). • Infectious diarrhea may be accompanied by fever, chills, vomiting, nausea, stomach discomfort, and tenesmus. A history of dizziness, syncope, or presyncope suggests volume depletion. Bloody stools (dysentery) indicate the presence of an invasive infection, including Shigella, Salmonella, Campylobacter, Shiga toxin-producing E. coli (notably in the absence of fever), or Yersinia. Shiga toxin-producing E. coli, particularly O157:H7, induces watery diarrhea that progresses to bloody diarrhea and is linked to the consumption of contaminated beef or produce in around fifty percent of cases. Fever is frequently absent. Yersinia and Salmonella can infect the terminal ileum and cecum, presenting with right lower quadrant pain and tenderness indicative of acute appendicitis. • Watery diarrhea is clinically ambiguous. Gastroenteritis resulting from an enterotoxin (food poisoning) may be attributed to S. aureus, B. cereus, or C. perfringens. These instances may manifest with isolated vomiting (S. aureus or C. perfringens) or watery diarrhea (B. cereus or C. perfringens). Fever is typically absent. The incubation period is brief (2–7 hours for S. aureus; 8–14 hours for C. perfringens; C. perfringens may exhibit either duration) and the overall duration is limited. Extraintestinal signs, like arthritis, dermatological diseases, or eye problems, indicate the presence of inflammatory bowel disease. • The cause of recent overseas travel is contingent upon the place, environment, and season. The predominant pathogens comprise enterotoxigenic E. coli, enteroaggregative E. coli, Campylobacter, Salmonella, and norovirus. The CDC Travelers' Health website or other travel medicine resources can assist in diagnostic evaluation.
PHYSICAL EXAMINATION • Evaluate blood pressure, heart rate, respiration rate, temperature, and mental status to determine the severity. • Assess for indicators of dehydration such as xerostomia, impaired skin turgor, enophthalmos, reduced capillary refill time, low jugular venous pressure, or orthostatic hypotension. • Examine for abdominal discomfort, manifestations of peritonitis (guarding, rebound tenderness), hepatomegaly, and splenomegaly.
DIAGNOSTIC TESTS AND INTERPRETATION
Laboratory Initial Assessments
• The indications for diagnostic testing encompass the following: Fever, systemic sickness, hematochezia, dehydration, a confirmed or suspected outbreak of foodborne illness, recent international travel, immunosuppression, or recent antibiotic administration. Submit stool specimen for culture analysis. In the majority of microbiology laboratories, stool samples submitted for the culture of enteric pathogens will be analyzed for Shigella, Salmonella, and Campylobacter. Consequently, if there is a strong clinical suspicion for E. coli (STEC, ETEC, EPEC, EIEC), Yersinia, Vibrio, etc., inform the microbiology laboratory. The diagnostic yield of stool cultures varies between 1.5% and 5.6%. • In cases with bloody diarrhea, do stool cultures for Salmonella, Shigella, Campylobacter, and Shiga toxin-producing E. coli, and conduct an immunoassay for Shiga toxin. Upon isolation of E. coli, dispatch to a reference laboratory for serotyping. • In cases of recent antibiotic use, hospitalization, daycare exposure, or chemotherapy, stool specimens should be analyzed for C. difficile toxins A and B. For diarrhea lasting over 7 days, collect numerous stool specimens for ova and parasite analysis, specifically targeting Giardia, Cryptosporidium, Isospora belli, and Cyclospora. Evaluate noninfectious etiology. In individuals with AIDS or immunosuppression, further test for microsporidia, Mycobacterium avium.
complex, and CMV. • A positive fecal test for polymorphonuclear cells indicates inflammatory diarrhea. Subsequent Actions & Unique Considerations In cases of dehydration or severe sickness, assess serum electrolytes, renal function, hepatic function, total blood count, and blood cultures. Imaging If the diagnosis is ambiguous, accompanied by critical illness, significant abdominal pain, or signs of peritonitis, consider performing a CT scan with both oral and intravenous contrast. Diagnostic Procedures and Additional Methods For additional assessment, contemplate upper gastrointestinal endoscopy or colonoscopy accompanied by diagnostic biopsies.
DIFFERENTIAL DIAGNOSIS • Acute inflammatory diarrheal syndrome may also arise from noninfectious causes, including ulcerative colitis, Crohn’s disease, radiation or ischemic colitis, partial bowel obstruction, diverticulitis, laxative abuse, rectosigmoid abscess, Whipple’s disease, pernicious anemia, diabetes, malabsorption, scleroderma, or celiac sprue. Diarrhea and fever may also arise from infections beyond the gastrointestinal tract, such as malaria or sepsis.
THERAPY PHARMACEUTICALS
The major elements of treatment consist of fluids and antibiotics. Oral rehydration constitutes the most suitable and cost-effective management strategy for both developing and wealthy nations. Intravenous volume repletion is warranted in cases of severe dehydration or significant electrolyte imbalance. The rice-based oral solution is more effective in adults and children suffering from cholera. Antimicrobial therapy is warranted in cases of severe infection and is advised for persistent gastroenteritis, individuals over 65 years of age, immunocompromised patients, those with prosthetic devices, and in instances of invasive infections, excluding those caused by Shiga toxin-producing E. coli. Empiric therapy: For febrile community-acquired invasive diarrhea or moderate to severe traveler's diarrhea, administer ciprofloxacin 500 mg twice day or levofloxacin 500 mg daily while awaiting stool investigations, unless Shiga toxin-producing E. coli is suspected. In the event of recent travel to Southeast Asia, investigate fluoroquinolone-resistant Campylobacter. If there has been recent antibiotic usage or nosocomial diarrhea, administer metronidazole or vancomycin while awaiting assay results for C. difficile toxin.
Chosen pathogens and their treatment: • Salmonella (non-typhi species) — Bacteremia manifests in 2–8% of cases. Administer treatment for severe disease in individuals under 12 months, over 50 years, with valvular disease, severe atherosclerosis, prosthetic devices, cancer, HIV, uremia, sickle cell disease, and other immunocompromised conditions. Ciprofloxacin 500 mg orally twice daily or levofloxacin 500 mg orally once daily for 5 to 7 days. If susceptible, provide TMP-SMX DS twice daily for 5–7 days, or ceftriaxone 2 g IV/IM daily for 5–7 days. Administer treatment for 14 days if the individual is immunocompromised. Antibiotics may augment shedding. • Shigellosis – provide ciprofloxacin 500 mg orally twice daily, or levofloxacin 500 mg once daily for 3 days, or if susceptible, TMP-SMX DS twice daily for 3 days. Administer treatment for 7 to 10 days in cases of severe disease or in immunocompromised individuals. • Campylobacter – provide erythromycin 500 mg bi-daily for a duration of 5 days. Significant fluoroquinolone resistance, particularly in Southeast Asia. • Escherichia coli, Shiga toxin-producing (STEC) – Avoid antibiotics as they may elevate the risk of hemolytic uremic syndrome (HUS).
Auxiliary care. • E. coli (ETEC, EPEC, EIEC) – provide ciprofloxacin 500 mg orally twice daily or levofloxacin 500 mg daily for a duration of 3 days. Administer TMP-SMX DS bi-daily for three days if susceptible. • Yersinia – antibiotics are generally unnecessary. For severe infections or immunocompromised patients, administer doxycycline in conjunction with an aminoglycoside, fluoroquinolone, or TMP-SMX. • C. difficile – discontinue superfluous antibiotics and use metronidazole 500 mg three times daily for moderate cases or vancomycin 125 mg four times daily for 10–14 days. Kindly refer to the pertinent subject. • Cholera: Fluid replenishment is essential. Examine local susceptibilities. Treatment options include doxycycline, tetracycline, TMP-SMX, or fluoroquinolone. Amebiasis: Administer metronidazole 750 mg three times daily for five days (ten days in severe cases), followed by paromomycin 500 mg three times daily for seven days, or iodoquinol 650 mg three times daily for twenty days. • Giardiasis: Metronidazole 250–750 mg administered thrice day for 7–10 days or tinidazole 2 g as a single dose • Cyclospora & Isospora – Administer TMP-SMX 1 DS bi-daily for a duration of 7–10 days. If immunocompromised, prolong treatment and contemplate suppression.
SUPPLEMENTARY THERAPY
Comprehensive Strategies • The majority of mild instances are self-resolving. Symptomatic treatment encompasses water and anti-motility medicines, including loperamide. Loperamide is the preferred antidiarrheal medication for people experiencing mild to moderate diarrhea without hematochezia. It is contraindicated in instances of severe inflammatory or bloody diarrhea, C. difficile infection, and in children under 2 years of age. Bismuth salicylate functions as an antisecretory agent and can diminish stool output in both children and adults. Concerns for Referral • In instances of severe or persistent diarrhea of indeterminate origin, consider consulting gastroenterology and/or infectious diseases specialists. • Document instances of Salmonella species, Shigella, Campylobacter, E. coli, cholera, cryptosporidiosis, cyclosporiasis, Vibrio species, and any suspected or confirmed outbreaks.
INPATIENT CONSIDERATIONS
Preliminary Stabilization Immediate rehydration and empirical antibiotics are necessary in cases of severe acute diarrhea accompanied by systemic toxicity. Criteria for Admission Admit individuals exhibiting severe dehydration or an inability to sustain fluid intake. Intravenous Fluids Intravenous volume repletion is warranted in cases of severe dehydration or when the patient exhibits changed mental status. Criteria for Discharge Patients may be discharged after fevers diminish for over 24 hours, vital signs stabilize, and the patient can sustain sufficient fluid and food intake.
CONTINUED MANAGEMENT POST-TREATMENT SUGGESTIONS
Evaluate and administer treatment to families exhibiting like symptoms.
DIET • Nutritional intake may commence four hours following the initiation of oral or intravenous hydration. • Provide regular, little portions of easily digestible food. Avoid hyperosmolar fruit juices, as they may worsen diarrhea.
INFORMATION FOR PATIENTS
Instruct patients on general food safety practices and methods to prevent foodborne infections, particularly during travel. OUTLOOK Gastrointestinal diseases account for about 900,000 hospitalizations and 6,000 fatalities in the United States each year.
COMPLICATIONS
Complications encompass dehydration, electrolyte imbalances, bacteremia and sepsis, malnutrition and vitamin deficiency, hemolytic uremic syndrome (HUS), and systemic amebiasis.
- Published on
Infectious Disease – Anorectql Infection
Anorectal infections pertain to infections of the anus and rectum, which constitute the terminal section of the large intestine.
Fournier’s gangrene encompasses any necrotizing infection of the external genitalia and perineum.
EPIDEMIOLOGY
Incidence
The prevalence of external anogenital lesions among organ transplant recipients is 1.5–2.3%, with a higher incidence in women. The majority of lesions are attributable to anogenital warts, succeeded by bowenoid papulosis, gigantic condyloma, and in situ cancer.
FACTORS OF RISK
Fournier’s gangrene frequently presents with a history of urinary infections, urologic instrumentation, or chronic colorectal illness. Moreover, the majority of patients
are impacted by comorbidities such as diabetes, alcoholism, or intravenous drug use, which impede host defense mechanisms.
COMPREHENSIVE PREVENTION
In immunocompromised patients exhibiting abscesses, perianal sepsis should be regarded as a potential source. Perianal fistulas in these patients should be incised or managed with fistulectomy, while perianal abscesses necessitate proper drainage to prevent necrotizing gangrene and metastatic abscesses.
Pathophysiology
Primary anal or rectal infection occurs in women and men who have sex with men following receptive anorectal intercourse. In women, rectal infection with lymphogranuloma venereum (or non-LGV) strains of Chlamydia trachomatis may occur through the contiguous dissemination of infected secretions along the perineum, similar to rectal gonococcal infections, or potentially via the pelvic lymphatics to the rectum.
Both herpes simplex viruses types 1 and 2 may induce symptomatic or asymptomatic infections in the rectal and perianal regions. Herpes infection proctitis is typically pertaining to anal intercourse. Nonetheless, asymptomatic perianal shedding of herpes simplex virus (HSV) is observed in both heterosexual men and women who do not engage in rectal intercourse.
Perianal warts are prevalent in men who engage in sexual relations with other men, yet they also occur in heterosexual men.
Perirectal abscesses frequently signify the migration of purulent material from the rectosigmoid region into the anal vicinity. Diverticulitis, Crohn's disease, ulcerative colitis, or prior surgical intervention may be the etiological factors.
Aerobic bacteria are present in most instances of Fournier’s gangrene, although mixed aerobic and anaerobic infections also occur.
ETIOLOGY • The predominant anorectal infections comprise bacterial and parasite infections (e.g., abscesses or soft-tissue infections) as well as sexually transmitted diseases. Many of these infections are also addressed in other chapters of the book.
• In men who engage in sexual activity with other men, the predominant causes of anorectal infection are as follows:
Anorectal gonococcal infection and herpes simplex virus (HSV)
- Infections caused by intestinal microorganisms, typically Giardia
Lamblia, Entamoeba histolytica, Campylobacter spp., and C. trachomatis - Syphilis Rectal lesions frequently occur in HIV-infected individuals, especially perirectal ulcers and erosions resulting from the reactivation of HSV infection. Additional rectal lesions frequently observed in HIV-infected individuals encompass condyloma acuminatum, Kaposi's sarcoma, and intraepithelial neoplasia.
FREQUENTLY CO-OCCURRING CONDITIONS
• Type I Diabetes Mellitus • Type II Diabetes Mellitus
HISTORY OF DIAGNOSIS
Symptoms of herpes simplex proctitis encompass anorectal pain, anorectal discharge, tenesmus, and constipation. Disproportionate pain relative to cutaneous manifestations may occur in Fournier’s gangrene.
PHYSICAL EXAM
• The primary presentations of anogenital warts are cauliflower-like condyloma acuminata typically affecting moist surfaces; keratotic and smooth papular warts, generally located on dry surfaces; and subclinical "flat" warts, which may appear on any mucosal or cutaneous surface.
Fournier’s gangrene is marked by localized gangrene and significant enlargement of the scrotum and penis, extending into the perineum, abdominal wall, and legs.
• Blisters • Bullae • Erythema
DIAGNOSTIC TESTS AND INTERPRETATION
Laboratory Initial laboratory assessments
Anorectal swab specimens can assist in the diagnosis of C. trachomatis infections with the application of PCR.
In cases of anorectal infection caused by HSV, sigmoidoscopy demonstrates ulcerative lesions in the distal 10 cm of the rectal mucosa. Rectal biopsies reveal mucosal ulceration, necrosis, polymorphonuclear and lymphocytic infiltration of the lamina propria, and, in rare instances, multinucleated intranuclear inclusion-bearing cells.
• Complete Blood Count (CBC) • Creatine Phosphokinase (CPK) • Erythrocyte Sedimentation Rate (ESR) • C-Reactive Protein (CRP) • Comprehensive Metabolic Panel (Chem 7) • Glucose • Arterial Blood Gas Analysis for critically unwell patients
Imaging modalities: • Computed Tomography (CT) scan • Magnetic Resonance Imaging (MRI)
DIFFERENTIAL DIAGNOSIS • Perianal donovanosis may mimic condylomata lata associated with secondary syphilis. Other venereal illnesses, especially syphilis, often coexist with donovanosis. In regions where donovanosis is endemic, the continued presence of suspected condylomata lata following adequate penicillin treatment for syphilis strongly indicates donovanosis. The differential diagnosis for anogenital warts encompasses condylomata lata associated with secondary syphilis, molluscum contagiosum, hirsutoid papillomatosis (pearly penile papules), fibroepitheliomas, and neoplasms.
THERAPEUTIC MEDICATION
• Cryotherapy may effectively eliminate warts that have not responded to podophyllin treatment. Perianal warts, however, exhibit poor responsiveness. Interferons have been utilized as adjuncts to various therapies.
Conservative treatment of local or systemic antibiotics is suitable for perianal abscess. Spontaneous clearance of granulomatous lesions is improbable, hence surgical intervention should be the preferred treatment.
Early and assertive surgical intervention is crucial for patients with Fournier’s gangrene, focusing on the excision of necrotic tissue, alleviation of compartment pressure, and acquisition of specimens for Gram staining as well as aerobic and anaerobic cultures. Empirical antibiotic therapy for mixed aerobic–anaerobic infections may include clindamycin (900 mg intravenously three times daily), ampicillin or ampicillin/sulbactam (2–3 g intravenously every six hours), in addition to gentamicin (1.0–1.5 mg/kg three times daily). Hyperbaric oxygen therapy may also be beneficial in cases of gas gangrene caused by clostridial species. The duration of therapy is variable; nonetheless, antibiotics must be administered until all indications of infection are resolved.
Systemic toxicity has been resolved, and all necrotic tissue has been excised.
OPERATIVE INTERVENTIONS/ADDITIONAL PROCEDURES
An early surgical consultation is essential for patients suspected of or diagnosed with Fournier’s gangrene.
INPATIENT CONSIDERATIONS
Preliminary Stabilization
Patients diagnosed with Fournier’s gangrene may necessitate hospitalization to the Intensive Care Unit (ICU).
CONTINUOUS MANAGEMENT POST-TREATMENT GUIDELINES
Anal warts and HIV infection are independent risk factors for cytologic abnormalities. Individuals at elevated risk for anal abnormalities comprise men with anal human papillomavirus infection and a history of intravenous drug use. Certain authorities recommend that these individuals, together with organ transplant recipients infected with oncogenic human papillomavirus, should be prioritized for anal cytology screening to detect and manage potentially precancerous anal conditions.
COMPLICATIONS
• Epidermodysplasia verruciformis is an uncommon autosomal recessive disorder marked by the inability to regulate human papillomavirus infection. Patients regularly get atypical human papillomavirus strains and commonly develop cutaneous squamous cell carcinomas, especially in sun-exposed regions. The lesions resemble flat warts or macules akin to those.
Pityriasis versicolor consequences include irritation and, at times, bleeding associated with warts. Warts may, in uncommon instances, become secondarily infected by bacteria or fungi. Extensive clusters of warts may induce mechanical complications, such as blockage of the delivery canal.
Perianal sepsis should consistently be considered as a potential source of infection in HIV-infected individuals, particularly in those with diminished CD4 cell levels. Fournier’s gangrene may lead to septicemia and has fatality rates ranging from 22% to 66%.
Anorectal infections pertain to infections of the anus and rectum, which constitute the terminal section of the large intestine.
Fournier’s gangrene encompasses any necrotizing infection of the external genitalia and perineum.
EPIDEMIOLOGY
Incidence
The prevalence of external anogenital lesions among organ transplant recipients is 1.5–2.3%, with a higher incidence in women. The majority of lesions are attributable to anogenital warts, succeeded by bowenoid papulosis, gigantic condyloma, and in situ cancer.
FACTORS OF RISK
Fournier’s gangrene frequently presents with a history of urinary infections, urologic instrumentation, or chronic colorectal illness. Moreover, the majority of patients
are impacted by comorbidities such as diabetes, alcoholism, or intravenous drug use, which impede host defense mechanisms.
COMPREHENSIVE PREVENTION
In immunocompromised patients exhibiting abscesses, perianal sepsis should be regarded as a potential source. Perianal fistulas in these patients should be incised or managed with fistulectomy, while perianal abscesses necessitate proper drainage to prevent necrotizing gangrene and metastatic abscesses.
Pathophysiology
Primary anal or rectal infection occurs in women and men who have sex with men following receptive anorectal intercourse. In women, rectal infection with lymphogranuloma venereum (or non-LGV) strains of Chlamydia trachomatis may occur through the contiguous dissemination of infected secretions along the perineum, similar to rectal gonococcal infections, or potentially via the pelvic lymphatics to the rectum.
Both herpes simplex viruses types 1 and 2 may induce symptomatic or asymptomatic infections in the rectal and perianal regions. Herpes infection proctitis is typically pertaining to anal intercourse. Nonetheless, asymptomatic perianal shedding of herpes simplex virus (HSV) is observed in both heterosexual men and women who do not engage in rectal intercourse.
Perianal warts are prevalent in men who engage in sexual relations with other men, yet they also occur in heterosexual men.
Perirectal abscesses frequently signify the migration of purulent material from the rectosigmoid region into the anal vicinity. Diverticulitis, Crohn's disease, ulcerative colitis, or prior surgical intervention may be the etiological factors.
Aerobic bacteria are present in most instances of Fournier’s gangrene, although mixed aerobic and anaerobic infections also occur.
ETIOLOGY • The predominant anorectal infections comprise bacterial and parasite infections (e.g., abscesses or soft-tissue infections) as well as sexually transmitted diseases. Many of these infections are also addressed in other chapters of the book.
• In men who engage in sexual activity with other men, the predominant causes of anorectal infection are as follows:
Anorectal gonococcal infection and herpes simplex virus (HSV)
- Infections caused by intestinal microorganisms, typically Giardia
Lamblia, Entamoeba histolytica, Campylobacter spp., and C. trachomatis - Syphilis Rectal lesions frequently occur in HIV-infected individuals, especially perirectal ulcers and erosions resulting from the reactivation of HSV infection. Additional rectal lesions frequently observed in HIV-infected individuals encompass condyloma acuminatum, Kaposi's sarcoma, and intraepithelial neoplasia.
FREQUENTLY CO-OCCURRING CONDITIONS
• Type I Diabetes Mellitus • Type II Diabetes Mellitus
HISTORY OF DIAGNOSIS
Symptoms of herpes simplex proctitis encompass anorectal pain, anorectal discharge, tenesmus, and constipation. Disproportionate pain relative to cutaneous manifestations may occur in Fournier’s gangrene.
PHYSICAL EXAM
• The primary presentations of anogenital warts are cauliflower-like condyloma acuminata typically affecting moist surfaces; keratotic and smooth papular warts, generally located on dry surfaces; and subclinical "flat" warts, which may appear on any mucosal or cutaneous surface.
Fournier’s gangrene is marked by localized gangrene and significant enlargement of the scrotum and penis, extending into the perineum, abdominal wall, and legs.
• Blisters • Bullae • Erythema
DIAGNOSTIC TESTS AND INTERPRETATION
Laboratory Initial laboratory assessments
Anorectal swab specimens can assist in the diagnosis of C. trachomatis infections with the application of PCR.
In cases of anorectal infection caused by HSV, sigmoidoscopy demonstrates ulcerative lesions in the distal 10 cm of the rectal mucosa. Rectal biopsies reveal mucosal ulceration, necrosis, polymorphonuclear and lymphocytic infiltration of the lamina propria, and, in rare instances, multinucleated intranuclear inclusion-bearing cells.
• Complete Blood Count (CBC) • Creatine Phosphokinase (CPK) • Erythrocyte Sedimentation Rate (ESR) • C-Reactive Protein (CRP) • Comprehensive Metabolic Panel (Chem 7) • Glucose • Arterial Blood Gas Analysis for critically unwell patients
Imaging modalities: • Computed Tomography (CT) scan • Magnetic Resonance Imaging (MRI)
DIFFERENTIAL DIAGNOSIS • Perianal donovanosis may mimic condylomata lata associated with secondary syphilis. Other venereal illnesses, especially syphilis, often coexist with donovanosis. In regions where donovanosis is endemic, the continued presence of suspected condylomata lata following adequate penicillin treatment for syphilis strongly indicates donovanosis. The differential diagnosis for anogenital warts encompasses condylomata lata associated with secondary syphilis, molluscum contagiosum, hirsutoid papillomatosis (pearly penile papules), fibroepitheliomas, and neoplasms.
THERAPEUTIC MEDICATION
• Cryotherapy may effectively eliminate warts that have not responded to podophyllin treatment. Perianal warts, however, exhibit poor responsiveness. Interferons have been utilized as adjuncts to various therapies.
Conservative treatment of local or systemic antibiotics is suitable for perianal abscess. Spontaneous clearance of granulomatous lesions is improbable, hence surgical intervention should be the preferred treatment.
Early and assertive surgical intervention is crucial for patients with Fournier’s gangrene, focusing on the excision of necrotic tissue, alleviation of compartment pressure, and acquisition of specimens for Gram staining as well as aerobic and anaerobic cultures. Empirical antibiotic therapy for mixed aerobic–anaerobic infections may include clindamycin (900 mg intravenously three times daily), ampicillin or ampicillin/sulbactam (2–3 g intravenously every six hours), in addition to gentamicin (1.0–1.5 mg/kg three times daily). Hyperbaric oxygen therapy may also be beneficial in cases of gas gangrene caused by clostridial species. The duration of therapy is variable; nonetheless, antibiotics must be administered until all indications of infection are resolved.
Systemic toxicity has been resolved, and all necrotic tissue has been excised.
OPERATIVE INTERVENTIONS/ADDITIONAL PROCEDURES
An early surgical consultation is essential for patients suspected of or diagnosed with Fournier’s gangrene.
INPATIENT CONSIDERATIONS
Preliminary Stabilization
Patients diagnosed with Fournier’s gangrene may necessitate hospitalization to the Intensive Care Unit (ICU).
CONTINUOUS MANAGEMENT POST-TREATMENT GUIDELINES
Anal warts and HIV infection are independent risk factors for cytologic abnormalities. Individuals at elevated risk for anal abnormalities comprise men with anal human papillomavirus infection and a history of intravenous drug use. Certain authorities recommend that these individuals, together with organ transplant recipients infected with oncogenic human papillomavirus, should be prioritized for anal cytology screening to detect and manage potentially precancerous anal conditions.
COMPLICATIONS
• Epidermodysplasia verruciformis is an uncommon autosomal recessive disorder marked by the inability to regulate human papillomavirus infection. Patients regularly get atypical human papillomavirus strains and commonly develop cutaneous squamous cell carcinomas, especially in sun-exposed regions. The lesions resemble flat warts or macules akin to those.
Pityriasis versicolor consequences include irritation and, at times, bleeding associated with warts. Warts may, in uncommon instances, become secondarily infected by bacteria or fungi. Extensive clusters of warts may induce mechanical complications, such as blockage of the delivery canal.
Perianal sepsis should consistently be considered as a potential source of infection in HIV-infected individuals, particularly in those with diminished CD4 cell levels. Fournier’s gangrene may lead to septicemia and has fatality rates ranging from 22% to 66%.
- Published on
Infectious Disease - Amebiasis
Protozoan infection induced by Entamoeba histolytica. Infection by these organisms results in diarrhea, colitis, and occasionally, extra-intestinal symptoms such as liver abscesses.
• Symptomatic illness manifests in fewer than 10% of affected persons. A minimal proportion of individuals with intestinal infections will progress to invasive illness.
Epidemiology
Frequency
Approximately ten percent of the global population is thought to be infected with E. histolytica.
• Prevalence varies from less than 5% in developed nations to 20–30% in tropical regions.
The estimated prevalence in the US is approximately 4%.
The disease manifests across all age groups and affects both genders equally.
RISK FACTORS • Risk factors in endemic regions encompass: – Low socioeconomic status – Inadequate sanitation
– Overcrowding • In nations with low prevalence:
- Immigrants or travelers from endemic areas – Institutionalized individuals – Males engaging in sexual relations with other males
• Risk factors linked to serious disease: - Newborns – Gestation
Corticosteroid treatment; malnutrition.
COMPREHENSIVE PREVENTION
• Humans constitute the sole reservoir of the infection.
Contaminated water or vegetables frequently serve as sources of infection in humans.
Cysts are not eliminated by chlorine; boiling water is essential for decontamination.
• Refrain from consuming polluted water and food. • Ensure that vegetables are thoroughly cleansed with potable water or treated with detergent and immersed in acetic acid or vinegar.
PATHOPHYSIOLOGY
• Infection transmits through the fecal–oral pathway • The organism manifests in two forms:
Trophozoite possessing a singular nucleus, with or without swallowed erythrocytes.
Cyst with four nuclei
The ingestion of the cyst leads to excystation in the small intestine. Trophozoites are generated, infecting the colon and causing symptoms.
• Under adverse conditions, the trophozoite encysts, and the cyst form is excreted in feces.
Cysts persist in a damp environment for several months.
• The majority of individuals infected with the bacterium exhibit minimal invasion of the intestinal mucosa and remain asymptomatic (cyst passers).
Patients exhibiting colonic invasion present with flask-shaped colonic ulcers.
ETIOLOGY • E. histolytica is one of the several Entamoeba species that infect people.
Nonpathogenic species encompass Entamoeba dispar, Entamoeba moshkovskii (both morphologically indistinguishable), Entamoeba hartmanni, and Entamoeba coli.
HISTORY OF DIAGNOSIS
• Patients exhibit symptoms of invasive illness within four weeks following the intake of cysts.
Amebic liver abscess typically requires approximately three months for development.
• Certain patients harbor the germs for extended durations prior to exhibiting notable clinical symptoms. • Intestinal disorder – Asymptomatic infection
— Symptomatic non-invasive infection
- Symptoms are minor; diarrhea is the sole manifestation. - Amebic colitis (dysentery) - Crampy abdominal discomfort - Hemorrhagic, mucoid diarrhea - Rectal hemorrhage may accompany diarrhea, particularly in pediatric patients - Fever is present in one-third of affected individuals – Weight reduction – Anorexia nervosa
• Extra-intestinal disease – Extra-intestinal amebiasis can impact the liver (abscess), spleen, lungs, or brain.
Amebic liver abscess manifests with fever and right upper quadrant pain.
ache in the upper quadrant. Fifty percent of patients with amebic liver abscess exhibit no prior history of colitis.
– Occasionally, the rupture of the abscess may result in peritonitis.
– Rupture of the liver abscess into the pleural cavity results in empyema. Patients exhibit fever, dyspnea, and pleuritic thoracic pain.
Cerebral amebiasis: Nausea, vomiting, cephalalgia, alterations in mental condition
PHYSICAL EXAMINATION
• Colitis – Widespread abdominal pain – Distension, rebound tenderness in severe colitis/perforation • Liver abscess – pain upon palpation of the liver Hepatomegaly - Jaundice is infrequent
DIAGNOSTIC TESTS AND INTERPRETATION
Laboratory
• Stool microscopy and O&P examination may reveal the presence of stool leukocytes.
- Intracytoplasmic erythrocytes within trophozoites (observed)
In E. histolytica and E. dispar, a wet mount for motile trophozoites and formal-ether concentration, followed by an iodine-stained deposit, enhances the probability of finding cysts.
– To enhance the efficacy of microscopic diagnosis, many samples must be analyzed. • Antigen detection – Fecal antigen identified with ELISA. More sensitive than O&P, however less effective than PCR. Requires either fresh or frozen specimens.
Applicable in hepatic abscess fluid.
– The TechLab E. histolytica II ELISA differentiates between pathogenic and nonpathogenic amebae• Serology – Beneficial in diagnosing liver abscess and invasive colonic illness – ELISA (most frequently utilized), indirect immunofluorescent assay, indirect hemagglutination assay – False positives in the early stages of the disease – Titers persist at elevated levels for years – In endemic regions, high seropositivity precludes differentiation between active and prior infection.
• Culture is conducted exclusively in research laboratories. • PCR – Real-time PCR is technically intricate yet exhibits more sensitivity than the stool antigen.
- Applicable in hepatic abscess fluid. • Additional laboratory examinations
Leukocytosis absent of eosinophilia is frequently observed in individuals with invasive amebic illness. Elevated alkaline phosphatase levels and moderately increased transaminases are noted in liver abscess cases.
Imaging
Imaging modalities, including ultrasound, CT, and MRI scans, are beneficial in evaluating patients with suspected amebic liver abscess. The amebic abscess is typically situated in the right lobe, specifically in the right upper posterior section of the liver.
Diagnostic Procedures and Additional Methods
• Colonoscopy and biopsy for colonic pathology – Results may appear normal in the first stages of the condition
– Fragile, ulcerated mucosa exhibiting punctate hemorrhages – Lateral infiltration into the submucosal tissues results in the distinctive flask-shaped ulcer associated with amebic colitis – Amebomas manifest as annular lesions
The aspiration of a liver abscess produces dark, odorless, sterile pus, typically referred to as "anchovy paste," which may contain trophozoites. Aspiration of liver abscesses frequently does not yield the organism, as it resides within the abscess walls.
Pathological Observations
Intestinal biopsy specimens obtained from the margins of ulcers must be assessed for motile trophozoites.
• The biopsy reveals mucosal thickening with many distinct ulcers interspersed among areas of normal-appearing mucosa.
DIFFERENTIAL DIAGNOSIS
• Ulcerative colitis • Colorectal carcinoma • Crohn's disease • Diverticulitis • Abdominal abscess • Irritable bowel syndrome • Pyogenic abscess • Hepatoma • Echinococcal liver cyst
MEDICATION FOR TREATMENT
• Asymptomatic disease – Intra-luminal carriage necessitates treatment due to the potential risk of invasive disease.
Paromomycin 500 mg orally three times day for seven days should be used as the first-line treatment.
Diloxanide furoate 500 mg three times daily for 10 days Iodoquinol 650 mg orally three times daily for 20 days
• Colitis – Metronidazole 750 mg orally three times daily for 10 days or tinidazole 1 g orally twice daily for 3 days, followed by one of the subsequent treatments:
Iodoquinol 650 mg orally three times daily for 20 days
Paromomycin 500 mg orally three times daily for seven days • Liver abscess – Administer Metronidazole 750 mg orally or intravenously three times daily for 10 days, followed by Iodoquinol 650 mg orally three times daily for 20 days
CLINICAL INTERVENTIONS/ADDITIONAL PROCEDURES
For a substantial abscess (>3 cm), aspiration and needle intervention
Drainage is warranted. Minor abscesses dissolve with medical intervention.
CONTINUED MANAGEMENT POST-TREATMENT SUGGESTIONS
Patients undergoing treatment for liver abscesses should receive follow-up ultrasounds to confirm cyst clearance, which may require many months.
OUTLOOK
Amebiasis presents significant morbidity and mortality, particularly in underdeveloped nations.
COMPLICATIONS
Fulminant colitis accompanied with toxic megacolon, perforation, and peritonitis is uncommon however thoroughly documented.
Amebomas are mass lesions located in the colon, frequently found in the cecum or ascending colon, resulting from inflammation associated with amebic colitis. Amebomas can lead to blockage and may mimic colon cancer.
• Ruptured liver abscess with diaphragm perforation resulting in pleural or pericardial illness.
Protozoan infection induced by Entamoeba histolytica. Infection by these organisms results in diarrhea, colitis, and occasionally, extra-intestinal symptoms such as liver abscesses.
• Symptomatic illness manifests in fewer than 10% of affected persons. A minimal proportion of individuals with intestinal infections will progress to invasive illness.
Epidemiology
Frequency
Approximately ten percent of the global population is thought to be infected with E. histolytica.
• Prevalence varies from less than 5% in developed nations to 20–30% in tropical regions.
The estimated prevalence in the US is approximately 4%.
The disease manifests across all age groups and affects both genders equally.
RISK FACTORS • Risk factors in endemic regions encompass: – Low socioeconomic status – Inadequate sanitation
– Overcrowding • In nations with low prevalence:
- Immigrants or travelers from endemic areas – Institutionalized individuals – Males engaging in sexual relations with other males
• Risk factors linked to serious disease: - Newborns – Gestation
Corticosteroid treatment; malnutrition.
COMPREHENSIVE PREVENTION
• Humans constitute the sole reservoir of the infection.
Contaminated water or vegetables frequently serve as sources of infection in humans.
Cysts are not eliminated by chlorine; boiling water is essential for decontamination.
• Refrain from consuming polluted water and food. • Ensure that vegetables are thoroughly cleansed with potable water or treated with detergent and immersed in acetic acid or vinegar.
PATHOPHYSIOLOGY
• Infection transmits through the fecal–oral pathway • The organism manifests in two forms:
Trophozoite possessing a singular nucleus, with or without swallowed erythrocytes.
Cyst with four nuclei
The ingestion of the cyst leads to excystation in the small intestine. Trophozoites are generated, infecting the colon and causing symptoms.
• Under adverse conditions, the trophozoite encysts, and the cyst form is excreted in feces.
Cysts persist in a damp environment for several months.
• The majority of individuals infected with the bacterium exhibit minimal invasion of the intestinal mucosa and remain asymptomatic (cyst passers).
Patients exhibiting colonic invasion present with flask-shaped colonic ulcers.
ETIOLOGY • E. histolytica is one of the several Entamoeba species that infect people.
Nonpathogenic species encompass Entamoeba dispar, Entamoeba moshkovskii (both morphologically indistinguishable), Entamoeba hartmanni, and Entamoeba coli.
HISTORY OF DIAGNOSIS
• Patients exhibit symptoms of invasive illness within four weeks following the intake of cysts.
Amebic liver abscess typically requires approximately three months for development.
• Certain patients harbor the germs for extended durations prior to exhibiting notable clinical symptoms. • Intestinal disorder – Asymptomatic infection
— Symptomatic non-invasive infection
- Symptoms are minor; diarrhea is the sole manifestation. - Amebic colitis (dysentery) - Crampy abdominal discomfort - Hemorrhagic, mucoid diarrhea - Rectal hemorrhage may accompany diarrhea, particularly in pediatric patients - Fever is present in one-third of affected individuals – Weight reduction – Anorexia nervosa
• Extra-intestinal disease – Extra-intestinal amebiasis can impact the liver (abscess), spleen, lungs, or brain.
Amebic liver abscess manifests with fever and right upper quadrant pain.
ache in the upper quadrant. Fifty percent of patients with amebic liver abscess exhibit no prior history of colitis.
– Occasionally, the rupture of the abscess may result in peritonitis.
– Rupture of the liver abscess into the pleural cavity results in empyema. Patients exhibit fever, dyspnea, and pleuritic thoracic pain.
Cerebral amebiasis: Nausea, vomiting, cephalalgia, alterations in mental condition
PHYSICAL EXAMINATION
• Colitis – Widespread abdominal pain – Distension, rebound tenderness in severe colitis/perforation • Liver abscess – pain upon palpation of the liver Hepatomegaly - Jaundice is infrequent
DIAGNOSTIC TESTS AND INTERPRETATION
Laboratory
• Stool microscopy and O&P examination may reveal the presence of stool leukocytes.
- Intracytoplasmic erythrocytes within trophozoites (observed)
In E. histolytica and E. dispar, a wet mount for motile trophozoites and formal-ether concentration, followed by an iodine-stained deposit, enhances the probability of finding cysts.
– To enhance the efficacy of microscopic diagnosis, many samples must be analyzed. • Antigen detection – Fecal antigen identified with ELISA. More sensitive than O&P, however less effective than PCR. Requires either fresh or frozen specimens.
Applicable in hepatic abscess fluid.
– The TechLab E. histolytica II ELISA differentiates between pathogenic and nonpathogenic amebae• Serology – Beneficial in diagnosing liver abscess and invasive colonic illness – ELISA (most frequently utilized), indirect immunofluorescent assay, indirect hemagglutination assay – False positives in the early stages of the disease – Titers persist at elevated levels for years – In endemic regions, high seropositivity precludes differentiation between active and prior infection.
• Culture is conducted exclusively in research laboratories. • PCR – Real-time PCR is technically intricate yet exhibits more sensitivity than the stool antigen.
- Applicable in hepatic abscess fluid. • Additional laboratory examinations
Leukocytosis absent of eosinophilia is frequently observed in individuals with invasive amebic illness. Elevated alkaline phosphatase levels and moderately increased transaminases are noted in liver abscess cases.
Imaging
Imaging modalities, including ultrasound, CT, and MRI scans, are beneficial in evaluating patients with suspected amebic liver abscess. The amebic abscess is typically situated in the right lobe, specifically in the right upper posterior section of the liver.
Diagnostic Procedures and Additional Methods
• Colonoscopy and biopsy for colonic pathology – Results may appear normal in the first stages of the condition
– Fragile, ulcerated mucosa exhibiting punctate hemorrhages – Lateral infiltration into the submucosal tissues results in the distinctive flask-shaped ulcer associated with amebic colitis – Amebomas manifest as annular lesions
The aspiration of a liver abscess produces dark, odorless, sterile pus, typically referred to as "anchovy paste," which may contain trophozoites. Aspiration of liver abscesses frequently does not yield the organism, as it resides within the abscess walls.
Pathological Observations
Intestinal biopsy specimens obtained from the margins of ulcers must be assessed for motile trophozoites.
• The biopsy reveals mucosal thickening with many distinct ulcers interspersed among areas of normal-appearing mucosa.
DIFFERENTIAL DIAGNOSIS
• Ulcerative colitis • Colorectal carcinoma • Crohn's disease • Diverticulitis • Abdominal abscess • Irritable bowel syndrome • Pyogenic abscess • Hepatoma • Echinococcal liver cyst
MEDICATION FOR TREATMENT
• Asymptomatic disease – Intra-luminal carriage necessitates treatment due to the potential risk of invasive disease.
Paromomycin 500 mg orally three times day for seven days should be used as the first-line treatment.
Diloxanide furoate 500 mg three times daily for 10 days Iodoquinol 650 mg orally three times daily for 20 days
• Colitis – Metronidazole 750 mg orally three times daily for 10 days or tinidazole 1 g orally twice daily for 3 days, followed by one of the subsequent treatments:
Iodoquinol 650 mg orally three times daily for 20 days
Paromomycin 500 mg orally three times daily for seven days • Liver abscess – Administer Metronidazole 750 mg orally or intravenously three times daily for 10 days, followed by Iodoquinol 650 mg orally three times daily for 20 days
CLINICAL INTERVENTIONS/ADDITIONAL PROCEDURES
For a substantial abscess (>3 cm), aspiration and needle intervention
Drainage is warranted. Minor abscesses dissolve with medical intervention.
CONTINUED MANAGEMENT POST-TREATMENT SUGGESTIONS
Patients undergoing treatment for liver abscesses should receive follow-up ultrasounds to confirm cyst clearance, which may require many months.
OUTLOOK
Amebiasis presents significant morbidity and mortality, particularly in underdeveloped nations.
COMPLICATIONS
Fulminant colitis accompanied with toxic megacolon, perforation, and peritonitis is uncommon however thoroughly documented.
Amebomas are mass lesions located in the colon, frequently found in the cecum or ascending colon, resulting from inflammation associated with amebic colitis. Amebomas can lead to blockage and may mimic colon cancer.
• Ruptured liver abscess with diaphragm perforation resulting in pleural or pericardial illness.
- Published on
Infectious Disease – Anaerobic Infections
• Anaerobic infections are induced by bacteria that necessitate diminished oxygen levels for proliferation.
Anaerobes linked to human diseases are aerotolerant; they can endure, but not proliferate, for up to 72 hours in an oxygen-rich environment.
Anaerobic bacteria inhabit mucosal membranes and are predominant in illnesses originating from mucosal and surrounding areas.
EPIDEMIOLOGY Incidence
Anaerobes comprise up to 10% of blood culture isolates in patients with clinically severe bacteremia. No incidence data exists for anaerobic infections at other sites.
FACTORS OF RISK
• Disruption of the mucosal barrier due to neoplasm, chemotherapy, radiation, neutropenia, graft-versus-host disease, surgical intervention, trauma, inflammatory bowel disease, diverticulitis, and appendicitis • Inadequate dental hygiene • Altered mental state, diminished gag reflex, and impaired swallowing
GENERAL PREVENTION
• Bowel preparation and preoperative antibacterial prophylaxis • Excellent oral hygiene • Aspiration precautions
Pathophysiology
• Translocation of indigenous flora into sterile sites resulting from mucosal membrane disruption • Translocation of oral flora into the lungs due to aspiration • Proliferation of obligate anaerobes during polymicrobial infections caused by reduced oxidation–reduction potential from aerobic organisms • Virulence factors allow anaerobic bacteria to induce abscess formation (e.g., Bacteroides fragilis: capsular polysaccharide), evade host defenses (e.g., Prevotella: IgA proteases), and adhere to cell surfaces
For instance, Porphyromonas gingivalis produces proteases, while Fusobacterium necrophorum generates leukotoxin and endotoxin.
ETIOLOGY
• B. fragilis is the predominant isolated anaerobic Gram-negative bacillus. Other Gram-negative bacteria include Fusobacterium, Prevotella, and Porphyromonas species. Peptostreptococcus species are the predominant Gram-positive cocci, while Clostridia represent the primary Gram-positive rods responsible for disease.
FREQUENTLY CO-OCCURRING CONDITIONS
• Dental infections – Pulpitis – Periapical and dental abscess – Perimandibular space infection • Gingivitis – Periodontitis – Periodontal abscess • Extension of periodontal infection resulting in maxillary sinus osteomyelitis or submandibular space infection • Vincent’s stomatitis (trench mouth) • Ludwig’s angina: Bilateral infection of the sublingual region and submandibular regions
Lemierre Syndrome: Infection of the posterior compartment of the lateral pharyngeal space by F. necrophorum, resulting in suppurative thrombophlebitis of the jugular vein and subsequent metastases, predominantly to the lungs.
• Chronic sinusitis and otitis media • Pleuropulmonary infections – Aspiration pneumonia – Necrotizing pneumonia – Lung abscess – Empyema
• Intra-abdominal infections – Peritonitis – Abscesses – Neutropenic colitis (Typhlitis) • Female genital tract infections – Pelvic inflammatory illness – Pelvic abscess – Septic abortion – Endometritis – Tubo-ovarian abscess – Postoperative infection
– Bacterial vaginosis – Pelvic cellulitis – Amnionitis – Septic thrombosis of pelvic veins • Central nervous system infections
Cerebral abscess, epidural abscess, subdural empyema
Anaerobic meningitis: Uncommon, indicative of shunt infection or parameningeal collection.
• Dermatological and subcutaneous conditions – Necrotizing fasciitis – Gas gangrene – Crepitant cellulitis – Bite injuries – Surgical incisions
– Diabetic foot infections – Pressure ulcers
• Bone and joint – Osteomyelitis and septic arthritis in proximity to affected soft tissue locations • Bacteremia – Resulting from an intra-abdominal, vaginal tract, respiratory tract, or soft tissue infection – B. fragilis is the most prevalent isolate
HISTORY OF DIAGNOSIS
• Abrupt emergence of sensitive, hemorrhaging gums, halitosis, unpleasant taste, fever, and cervical lymphadenopathy - Vincent’s stomatitis (trench mouth) • Pain in the submandibular and/or sublingual regions, trismus, and lateral or posterior displacement of the tongue leading to dysphagia and/or airway obstruction – Ludwig’s angina
• Nasopharyngitis or tonsillar abscess, succeeded 1–2 weeks later by pyrexia, submandibular angle lymphadenopathy, discomfort along the lateral portion of the sternocleidomastoid muscle, and pulmonary metastases.
Lemierre's syndrome
• Weight reduction, thoracic discomfort, or pleuritic pain - Empyema
• Persistent malaise, weight reduction, pyrexia, chills, malodorous sputum, and anemia – Anaerobic pulmonary abscess • Impaired cognitive function, dysphagia, chronic respiratory manifestations, weight reduction, pyrexia, and anemia
Aspiration pneumonia
• Neutropenia, right lower quadrant stomach discomfort, fever, diarrhea – Typhlitis • Lack of progress in the infectious process on an antibiotic regimen devoid of anaerobic activity – Indicative of anaerobes
PHYSICAL EXAMINATION
• Deteriorated dental condition – Prevalence of anaerobic oral microbiota with potential for translocation
• Gas in tissue, crepitus – Infection with gas-producing bacteria • Malodorous discharge • Infection near mucosal surfaces • Tissue necrosis, abscess development – Suggestive of anaerobic organisms DIAGNOSTIC TESTS & INTERPRETATION Laboratory
Anaerobes present significant challenges in cultivation and identification. In numerous instances, the anaerobic origin of an infection remains unverified.
• Cultural methodology
Specimens must be obtained while preventing contamination of the indigenous flora of mucosal surfaces.
- Liquids or tissues are preferred over swab specimens.
Air must be removed from the syringe utilized for aspiration, and the needle must be sealed.
– Utilization of anaerobic transport media. – Expedited processing of samples.
All specimens must undergo Gram staining; the absence of growth in culture alongside the presence of Gram-positive and Gram-negative organisms in Gram staining indicates the potential existence of anaerobic organisms.
Imaging • Radiographs – Presence of air–fluid levels, cavity formation, and gas in tissue • CT and/or MRI scans – Frequently essential for delineating anatomical location and disease extent
Diagnostic Procedures/Other: CT- or ultrasound-guided aspiration or biopsy
DIFFERENTIAL DIAGNOSIS
Anaerobic lung abscesses must be distinguished from mycobacterial infections.
TREATMENT
• The treatment comprises a combination of surgical interventions (resection, debridement, drainage) and antimicrobial therapy. • Antibiotics administered must encompass both aerobic and anaerobic bacteria due to the polymicrobial characteristics of numerous illnesses.
Empirical selection of antibiotic regimen based on infection type, Gram stain results, tissue penetration, and toxicity. Susceptibility testing is challenging because to anaerobic culture methodologies, prolonged turnaround times, and inadequate quality control.
• Susceptibility testing is advised for patients requiring extended antibiotic treatment: cerebral abscess, osteomyelitis, and infections associated with prosthetic devices. • Anaerobic infections originating from below the diaphragm should be managed with targeted therapy against B. fragilis. Members of the B. fragilis group exhibit resistance to penicillin.
Antimicrobial drugs effective against anaerobes include carbapenems, β-lactam/β-lactamase inhibitor combinations, and metronidazole (note that metronidazole is ineffective against Actinomyces spp., Propionibacterium spp., peptostreptococci, and microaerophilic streptococci).
• Rising incidence of antibiotic resistance in B. fragilis.
Resistance to cephamycins is 8–14%, clindamycin 26% and moxifloxacin 38%
CONTINUED MANAGEMENT POST-TREATMENT SUGGESTIONS
Patient Surveillance
Ensure sufficient drainage of abscesses with further imaging.
Surgical resection is warranted if drainage proves ineffective.
• Conduct repeat sampling if the infection does not respond to antimicrobial therapy to assess for drug-resistant organisms.
• Surveillance for antimicrobial drug toxicities.
COMPLICATIONS
Uninterrupted dissemination of untreated illnesses
• Anaerobic infections are induced by bacteria that necessitate diminished oxygen levels for proliferation.
Anaerobes linked to human diseases are aerotolerant; they can endure, but not proliferate, for up to 72 hours in an oxygen-rich environment.
Anaerobic bacteria inhabit mucosal membranes and are predominant in illnesses originating from mucosal and surrounding areas.
EPIDEMIOLOGY Incidence
Anaerobes comprise up to 10% of blood culture isolates in patients with clinically severe bacteremia. No incidence data exists for anaerobic infections at other sites.
FACTORS OF RISK
• Disruption of the mucosal barrier due to neoplasm, chemotherapy, radiation, neutropenia, graft-versus-host disease, surgical intervention, trauma, inflammatory bowel disease, diverticulitis, and appendicitis • Inadequate dental hygiene • Altered mental state, diminished gag reflex, and impaired swallowing
GENERAL PREVENTION
• Bowel preparation and preoperative antibacterial prophylaxis • Excellent oral hygiene • Aspiration precautions
Pathophysiology
• Translocation of indigenous flora into sterile sites resulting from mucosal membrane disruption • Translocation of oral flora into the lungs due to aspiration • Proliferation of obligate anaerobes during polymicrobial infections caused by reduced oxidation–reduction potential from aerobic organisms • Virulence factors allow anaerobic bacteria to induce abscess formation (e.g., Bacteroides fragilis: capsular polysaccharide), evade host defenses (e.g., Prevotella: IgA proteases), and adhere to cell surfaces
For instance, Porphyromonas gingivalis produces proteases, while Fusobacterium necrophorum generates leukotoxin and endotoxin.
ETIOLOGY
• B. fragilis is the predominant isolated anaerobic Gram-negative bacillus. Other Gram-negative bacteria include Fusobacterium, Prevotella, and Porphyromonas species. Peptostreptococcus species are the predominant Gram-positive cocci, while Clostridia represent the primary Gram-positive rods responsible for disease.
FREQUENTLY CO-OCCURRING CONDITIONS
• Dental infections – Pulpitis – Periapical and dental abscess – Perimandibular space infection • Gingivitis – Periodontitis – Periodontal abscess • Extension of periodontal infection resulting in maxillary sinus osteomyelitis or submandibular space infection • Vincent’s stomatitis (trench mouth) • Ludwig’s angina: Bilateral infection of the sublingual region and submandibular regions
Lemierre Syndrome: Infection of the posterior compartment of the lateral pharyngeal space by F. necrophorum, resulting in suppurative thrombophlebitis of the jugular vein and subsequent metastases, predominantly to the lungs.
• Chronic sinusitis and otitis media • Pleuropulmonary infections – Aspiration pneumonia – Necrotizing pneumonia – Lung abscess – Empyema
• Intra-abdominal infections – Peritonitis – Abscesses – Neutropenic colitis (Typhlitis) • Female genital tract infections – Pelvic inflammatory illness – Pelvic abscess – Septic abortion – Endometritis – Tubo-ovarian abscess – Postoperative infection
– Bacterial vaginosis – Pelvic cellulitis – Amnionitis – Septic thrombosis of pelvic veins • Central nervous system infections
Cerebral abscess, epidural abscess, subdural empyema
Anaerobic meningitis: Uncommon, indicative of shunt infection or parameningeal collection.
• Dermatological and subcutaneous conditions – Necrotizing fasciitis – Gas gangrene – Crepitant cellulitis – Bite injuries – Surgical incisions
– Diabetic foot infections – Pressure ulcers
• Bone and joint – Osteomyelitis and septic arthritis in proximity to affected soft tissue locations • Bacteremia – Resulting from an intra-abdominal, vaginal tract, respiratory tract, or soft tissue infection – B. fragilis is the most prevalent isolate
HISTORY OF DIAGNOSIS
• Abrupt emergence of sensitive, hemorrhaging gums, halitosis, unpleasant taste, fever, and cervical lymphadenopathy - Vincent’s stomatitis (trench mouth) • Pain in the submandibular and/or sublingual regions, trismus, and lateral or posterior displacement of the tongue leading to dysphagia and/or airway obstruction – Ludwig’s angina
• Nasopharyngitis or tonsillar abscess, succeeded 1–2 weeks later by pyrexia, submandibular angle lymphadenopathy, discomfort along the lateral portion of the sternocleidomastoid muscle, and pulmonary metastases.
Lemierre's syndrome
• Weight reduction, thoracic discomfort, or pleuritic pain - Empyema
• Persistent malaise, weight reduction, pyrexia, chills, malodorous sputum, and anemia – Anaerobic pulmonary abscess • Impaired cognitive function, dysphagia, chronic respiratory manifestations, weight reduction, pyrexia, and anemia
Aspiration pneumonia
• Neutropenia, right lower quadrant stomach discomfort, fever, diarrhea – Typhlitis • Lack of progress in the infectious process on an antibiotic regimen devoid of anaerobic activity – Indicative of anaerobes
PHYSICAL EXAMINATION
• Deteriorated dental condition – Prevalence of anaerobic oral microbiota with potential for translocation
• Gas in tissue, crepitus – Infection with gas-producing bacteria • Malodorous discharge • Infection near mucosal surfaces • Tissue necrosis, abscess development – Suggestive of anaerobic organisms DIAGNOSTIC TESTS & INTERPRETATION Laboratory
Anaerobes present significant challenges in cultivation and identification. In numerous instances, the anaerobic origin of an infection remains unverified.
• Cultural methodology
Specimens must be obtained while preventing contamination of the indigenous flora of mucosal surfaces.
- Liquids or tissues are preferred over swab specimens.
Air must be removed from the syringe utilized for aspiration, and the needle must be sealed.
– Utilization of anaerobic transport media. – Expedited processing of samples.
All specimens must undergo Gram staining; the absence of growth in culture alongside the presence of Gram-positive and Gram-negative organisms in Gram staining indicates the potential existence of anaerobic organisms.
Imaging • Radiographs – Presence of air–fluid levels, cavity formation, and gas in tissue • CT and/or MRI scans – Frequently essential for delineating anatomical location and disease extent
Diagnostic Procedures/Other: CT- or ultrasound-guided aspiration or biopsy
DIFFERENTIAL DIAGNOSIS
Anaerobic lung abscesses must be distinguished from mycobacterial infections.
TREATMENT
• The treatment comprises a combination of surgical interventions (resection, debridement, drainage) and antimicrobial therapy. • Antibiotics administered must encompass both aerobic and anaerobic bacteria due to the polymicrobial characteristics of numerous illnesses.
Empirical selection of antibiotic regimen based on infection type, Gram stain results, tissue penetration, and toxicity. Susceptibility testing is challenging because to anaerobic culture methodologies, prolonged turnaround times, and inadequate quality control.
• Susceptibility testing is advised for patients requiring extended antibiotic treatment: cerebral abscess, osteomyelitis, and infections associated with prosthetic devices. • Anaerobic infections originating from below the diaphragm should be managed with targeted therapy against B. fragilis. Members of the B. fragilis group exhibit resistance to penicillin.
Antimicrobial drugs effective against anaerobes include carbapenems, β-lactam/β-lactamase inhibitor combinations, and metronidazole (note that metronidazole is ineffective against Actinomyces spp., Propionibacterium spp., peptostreptococci, and microaerophilic streptococci).
• Rising incidence of antibiotic resistance in B. fragilis.
Resistance to cephamycins is 8–14%, clindamycin 26% and moxifloxacin 38%
CONTINUED MANAGEMENT POST-TREATMENT SUGGESTIONS
Patient Surveillance
Ensure sufficient drainage of abscesses with further imaging.
Surgical resection is warranted if drainage proves ineffective.
• Conduct repeat sampling if the infection does not respond to antimicrobial therapy to assess for drug-resistant organisms.
• Surveillance for antimicrobial drug toxicities.
COMPLICATIONS
Uninterrupted dissemination of untreated illnesses
- Published on
Infectious Disease -Adenovirus Infections
OVERVIEW
• Adenovirus infections are induced by double-stranded DNA viruses ranging from 70 to 80 nm in diameter. • Human adenoviruses are classified within the genus Mastadenovirus, with more than 50 serotypes.
EPIDEMIOLOGY Incidence • 80% of acute respiratory sickness cases are attributable to viral infections, predominantly rhinovirus, with adenovirus occurring less frequently. • Infections are most prevalent from autumn to spring.
RISK FACTORS • Adenovirus infection may be transmitted through inhalation of aerosolized virus, injection into conjunctival sacs, and likely via the fecal-oral pathway.
Adenoviruses are responsible for up to 5% of acute respiratory infections in children, but they account for less than 2% of respiratory disorders in adults.
• Specific adenovirus serotypes are linked to outbreaks of acute respiratory illness among military recruits during the winter and spring seasons.
• Antibodies are produced following infection and confer protection against reinfection with the same serotype. • Adenoviruses have been linked to disseminated disease and pneumonia in immunocompromised individuals, including those with AIDS, recipients of solid organ or bone marrow transplants, and children with congenital immunodeficiency syndromes.
The etiology of adenoviruses is defined by their distinctive morphology, which features an icosahedral shell made up of 20 equilateral triangular faces and 12 vertices.
Human adenoviruses are classified into six subgenera (A to F) based on DNA genome homology and other characteristics.
The adenovirus genome is a linear double-stranded DNA that encodes structural and nonstructural polypeptides. The replicative cycle of adenovirus can lead to either lytic infection of cells or the creation of a latent infection. • Certain viral strains can provoke oncogenic transformation. Tumor development has been shown in animals.
DIAGNOSTIC HISTORY
Adenoviruses induce various clinical disorders in children. The most prevalent condition is an acute upper respiratory tract infection characterized by significant rhinitis.
• Occasionally, lower respiratory tract diseases such as bronchiolitis and pneumonia manifest.
Adenoviruses can induce pharyngoconjunctival fever, a distinct acute febrile condition in children that typically manifests during outbreaks, predominantly at summer camps. A low-grade fever typically occurs during the initial 3–5 days, succeeded by rhinitis, pharyngitis, and cervical lymphadenopathy. The ailment often endures for 1 to 2 weeks and fades autonomously.
Pharyngitis has been linked to viral infection.
• In adults, acute respiratory disease has been the most commonly reported ailment. This ailment is characterized by a significant painful throat and a slow emergence of fever, frequently attaining 39°C. Cough is typically prevalent, and coryza along with regional lymphadenopathy is often observed.
Adenoviruses may also induce non-respiratory tract infections. Diseases: – Acute diarrheal sickness in young infants – Hemorrhagic cystitis – Epidemic keratoconjunctivitis
Immunocompromised patients with adenovirus pneumonia may exhibit a sudden onset of fever, chills, malaise, nonproductive cough, nausea, vomiting, diarrhea, abdominal discomfort, headache, and joint pain.
PHYSICAL EXAMINATION
• The physical examination may reveal pharyngeal edema, erythema, and tonsillar hypertrophy with minimal or absent exudate.
• In immunocompromised individuals, regional physical examination findings may be absent.
– Individuals with eye disorders may exhibit conjunctival irritation accompanied by discharge.
DIAGNOSTIC TESTS AND INTERPRETATION Laboratory
Preliminary laboratory examinations
A conclusive diagnosis of adenovirus infection is determined by cultural methods or the identification of the virus from locations such as the conjunctiva and oropharynx, or from sputum, urine, or feces.
• Viruses can be recognized in tissue culture through cytopathic alterations and particularly characterized using immunofluorescence or other immunological methods.
• Adenovirus strains linked to diarrheal illness in children necessitate specific tissue-culture cells for isolation or are detected using direct ELISA of stool samples. • Increases in serum antibodies can be evidenced through complement-fixation or neutralization assays, ELISA, or radioimmunoassay.
Imaging
Adenovirus pneumonia typically presents on chest radiographs as bilateral, diffuse interstitial infiltrates, with infrequent pleural effusions.
DIFFERENTIAL DIAGNOSIS
In many instances, diseases resulting from adenovirus infection cannot be distinguished from those caused by many other viral respiratory pathogens like Mycoplasma pneumoniae.
THERAPEUTIC PHARMACEUTICAL
Only symptomatic treatment and supportive therapy are available for adenovirus infections.
Live vaccinations have been created for adenovirus types 4 and 7 (given as live, unattenuated virus in enteric-coated capsules) and are utilized to manage outbreaks among military recruits. The management of adenovirus infections in immunocompromised individuals is typically supportive.
• • •
Severe adenovirus infections in immunocompromised individuals may be treated with cidofovir and a single administration of intravenous immunoglobulin. Intravenous gamma globulin has been utilized in the management of adenovirus infections in transplant recipients and immunocompromised individuals, with type-specific antibodies potentially contributing to the therapy of this illness.
Ribavirin or ganciclovir has been effectively utilized for treating adenovirus infections in both immunocompromised and immunocompetent individuals; nevertheless, the evidence supporting its efficiency is restricted to case studies.
CONTINUING CARE COMPLICATIONS
Adenovirus pneumonia in transplant recipients and immunocompromised individuals is linked to considerable morbidity and mortality, perhaps surpassing 60%.
ICD-9 CODES • 008.62 Enteritis attributable to adenovirus • 079.0 Adenovirus infection in conditions categorized elsewhere and of undetermined location • 480.0 Pneumonia resulting from adenovirus
OVERVIEW
• Adenovirus infections are induced by double-stranded DNA viruses ranging from 70 to 80 nm in diameter. • Human adenoviruses are classified within the genus Mastadenovirus, with more than 50 serotypes.
EPIDEMIOLOGY Incidence • 80% of acute respiratory sickness cases are attributable to viral infections, predominantly rhinovirus, with adenovirus occurring less frequently. • Infections are most prevalent from autumn to spring.
RISK FACTORS • Adenovirus infection may be transmitted through inhalation of aerosolized virus, injection into conjunctival sacs, and likely via the fecal-oral pathway.
Adenoviruses are responsible for up to 5% of acute respiratory infections in children, but they account for less than 2% of respiratory disorders in adults.
• Specific adenovirus serotypes are linked to outbreaks of acute respiratory illness among military recruits during the winter and spring seasons.
• Antibodies are produced following infection and confer protection against reinfection with the same serotype. • Adenoviruses have been linked to disseminated disease and pneumonia in immunocompromised individuals, including those with AIDS, recipients of solid organ or bone marrow transplants, and children with congenital immunodeficiency syndromes.
The etiology of adenoviruses is defined by their distinctive morphology, which features an icosahedral shell made up of 20 equilateral triangular faces and 12 vertices.
Human adenoviruses are classified into six subgenera (A to F) based on DNA genome homology and other characteristics.
The adenovirus genome is a linear double-stranded DNA that encodes structural and nonstructural polypeptides. The replicative cycle of adenovirus can lead to either lytic infection of cells or the creation of a latent infection. • Certain viral strains can provoke oncogenic transformation. Tumor development has been shown in animals.
DIAGNOSTIC HISTORY
Adenoviruses induce various clinical disorders in children. The most prevalent condition is an acute upper respiratory tract infection characterized by significant rhinitis.
• Occasionally, lower respiratory tract diseases such as bronchiolitis and pneumonia manifest.
Adenoviruses can induce pharyngoconjunctival fever, a distinct acute febrile condition in children that typically manifests during outbreaks, predominantly at summer camps. A low-grade fever typically occurs during the initial 3–5 days, succeeded by rhinitis, pharyngitis, and cervical lymphadenopathy. The ailment often endures for 1 to 2 weeks and fades autonomously.
Pharyngitis has been linked to viral infection.
• In adults, acute respiratory disease has been the most commonly reported ailment. This ailment is characterized by a significant painful throat and a slow emergence of fever, frequently attaining 39°C. Cough is typically prevalent, and coryza along with regional lymphadenopathy is often observed.
Adenoviruses may also induce non-respiratory tract infections. Diseases: – Acute diarrheal sickness in young infants – Hemorrhagic cystitis – Epidemic keratoconjunctivitis
Immunocompromised patients with adenovirus pneumonia may exhibit a sudden onset of fever, chills, malaise, nonproductive cough, nausea, vomiting, diarrhea, abdominal discomfort, headache, and joint pain.
PHYSICAL EXAMINATION
• The physical examination may reveal pharyngeal edema, erythema, and tonsillar hypertrophy with minimal or absent exudate.
• In immunocompromised individuals, regional physical examination findings may be absent.
– Individuals with eye disorders may exhibit conjunctival irritation accompanied by discharge.
DIAGNOSTIC TESTS AND INTERPRETATION Laboratory
Preliminary laboratory examinations
A conclusive diagnosis of adenovirus infection is determined by cultural methods or the identification of the virus from locations such as the conjunctiva and oropharynx, or from sputum, urine, or feces.
• Viruses can be recognized in tissue culture through cytopathic alterations and particularly characterized using immunofluorescence or other immunological methods.
• Adenovirus strains linked to diarrheal illness in children necessitate specific tissue-culture cells for isolation or are detected using direct ELISA of stool samples. • Increases in serum antibodies can be evidenced through complement-fixation or neutralization assays, ELISA, or radioimmunoassay.
Imaging
Adenovirus pneumonia typically presents on chest radiographs as bilateral, diffuse interstitial infiltrates, with infrequent pleural effusions.
DIFFERENTIAL DIAGNOSIS
In many instances, diseases resulting from adenovirus infection cannot be distinguished from those caused by many other viral respiratory pathogens like Mycoplasma pneumoniae.
THERAPEUTIC PHARMACEUTICAL
Only symptomatic treatment and supportive therapy are available for adenovirus infections.
Live vaccinations have been created for adenovirus types 4 and 7 (given as live, unattenuated virus in enteric-coated capsules) and are utilized to manage outbreaks among military recruits. The management of adenovirus infections in immunocompromised individuals is typically supportive.
• • •
Severe adenovirus infections in immunocompromised individuals may be treated with cidofovir and a single administration of intravenous immunoglobulin. Intravenous gamma globulin has been utilized in the management of adenovirus infections in transplant recipients and immunocompromised individuals, with type-specific antibodies potentially contributing to the therapy of this illness.
Ribavirin or ganciclovir has been effectively utilized for treating adenovirus infections in both immunocompromised and immunocompetent individuals; nevertheless, the evidence supporting its efficiency is restricted to case studies.
CONTINUING CARE COMPLICATIONS
Adenovirus pneumonia in transplant recipients and immunocompromised individuals is linked to considerable morbidity and mortality, perhaps surpassing 60%.
ICD-9 CODES • 008.62 Enteritis attributable to adenovirus • 079.0 Adenovirus infection in conditions categorized elsewhere and of undetermined location • 480.0 Pneumonia resulting from adenovirus
- Published on
Infectious Disease - Actinomycosis
FUNDAMENTAL DESCRIPTION
A persistent, slow-progressing, purulent, tissue-destructive infection characterized by the growth of lumps and sinuses, typically affecting the head and neck, but capable of influencing other regions such as the thorax and abdomen.
EPIDEMIOLOGY
Incidence • The documented incidence in the general population is approximately 1:300,000 in the United States and around 1:100,000 in Europe. • Infection manifests across all age groups, with a peak incidence during the middle decades of life. • The male-to-female ratio is 3:1.
RISK FACTORS: • Inadequate oral hygiene, dental interventions, oral surgical procedures, and
psychological injury
• Intrauterine contraceptive devices (all varieties; heightened risk if retained for over 2 years)
• Abdominal surgery, intra-abdominal inflammatory conditions (diverticulitis, appendicitis), foreign objects
Actinomycosis has been documented in contexts of malnutrition and immunodeficiency, including HIV infection, chronic granulomatous illness, and prolonged steroid usage.
Actinomycosis has been documented in patients with infected osteoradionecrosis and bisphosphonate-related mandibular osteonecrosis.
GENERAL PREVENTION
• Maintain optimal oral hygiene, including the elimination of dental plaque.
The identification of Gupta bodies or Actinomyces-like organisms (ALOs) in Papanicolaou cervicovaginal smears may assist in averting the progression of advanced pelvic disease in women with prolonged use of intrauterine contraceptive devices and symptoms indicative of early pelvic actinomycosis, including pain, abnormal bleeding, or unusual discharge. It is advised to remove the intrauterine device and administer a 2- to 3-week regimen of antibiotics in these instances.
• Patient isolation is unnecessary.
PATHOPHYSIOLOGY
Humans serve as the natural reservoir for actinomycosis pathogens.
The organisms often develop as saprophytes in the oral cavity, primarily within dental plaque and tonsillar crypts.
• Transmission likely happens through direct touch between individuals.
• The extraction of teeth or other trauma to the oral mucosa may trigger a localized infection caused by Actinomyces species.
The germs are likely aspirated and may occasionally result in lung actinomycosis.
• The majority of abdominal actinomycosis cases start in the appendix.
• While the precise incubation period remains undetermined, diagnosis typically occurs after extended durations. While an acute variant has been identified, chronic illness constitutes the predominant majority of patients.
• The disruption of the mucosal barrier appears essential for the first onset of the illness. It subsequently disseminates contiguously and/or hematogenously. Aspiration or contiguous dissemination from the cervical region results in pulmonary involvement. Foreign bodies and/or intestinal perforation resulting from appendicitis or diverticulitis contribute to the pathological processes in abdominal and pelvic diseases.
• Depending on the specific anatomical region involved, Oral/cervicofacial, thoracic, abdominal, pelvic, central nervous system (CNS), and disseminated forms of the disease are acknowledged. Muscle and bone involvement is owing to direct extension from surrounding tissue infection or, less commonly, as a result of trauma or infection dissemination.
ETIOLOGY
• Actinomyces are microaerophilic or anaerobic, filamentous, branching, Gram-positive, non-acid-fast bacilli.
• A. israelii is the most prevalent species of Actinomyces discovered in the pus and tissues of individuals afflicted with actinomycosis.
• A. naeslundii, A. meyeri, A. odontolyticus, and Propionibacterium propionica (Arachnia propionica) have been documented as causative agents of human actinomycosis.
• A. viscosus has been identified as a significant factor to the pathogenesis of periodontal disease. • Actinomyces are commensals of the oral cavity and female vaginal system. In most instances of actinomycosis, meticulous cultures produce polymicrobial isolates, predominantly comprising anaerobic constituents of the normal oral flora. These may function as copathogens in the pathological process.
DIAGNOSTIC HISTORY
• Discomfort, vaginal secretion, and/or hemorrhage (pelvic pathology) • Cephalalgia, localized neurological manifestations
• Symptoms are contingent upon the severity of the lesions and the affected organ/system. • Potential manifestations include pain, low-grade fever, and weight loss.
• Trismus (oral/cervicofacial condition) • Chest discomfort, cough (productive or non-productive), progressively worsening shortness of breath (thoracic condition) • Abdominal pain, alteration in bowel habits (abdominal condition)
PHYSICAL EXAM
The characteristic feature of the disease is the development of space-occupying lesions of diverse sizes, exhibiting variable levels of suppuration and/or fibrosis.
– Infiltration into neighboring tissues may transpire, along with outflow to nearby cavities or the skin through sinus development. Sinus conditions may be self-limiting and recurring pus typically contains yellowish "sulfur granules," observable both macroscopically and microscopically.
• Cervicofacial/oral pathology – The perimandibular area is predominantly affected; however, all regions of the head, neck, and oral cavity may be implicated, encompassing soft tissues, bones, salivary glands, thyroid, eyes (postoperative canaliculitis and endophthalmitis), and ears (chronic, myringotomy-resistant otitis media).
– The superficial skin may exhibit a purple, red, or bluish hue. • Thoracic disease – Arises from aspiration or, less commonly, contiguous spread from the cervical region. Indicators suggest a space-occupying lesion and/or pneumonitis, with pleural involvement (thickening, effusion, empyema) observed in over 50% of patients.
– The existence of several cavities and the engagement of the chest wall (including soft tissues and bones with sinus development) corroborate the diagnosis.
Mediastinal involvement, primarily affecting heart tissues, and spinal involvement may occur.
• Abdominal pathology – Symptoms include the presence of a firm or hard mass lesion, typically located in the right iliac fossa, sometimes subsequent to ruptured appendicitis.
- Disease of the left iliac fossa is a consequence of diverticulitis.
Perirectal or perianal illness manifests as chronic recurrent abscesses and the establishment of sinuses or fistulas in the pertinent area are noted. Peritonitis is uncommon.
• Pelvic disease – Manifestations include pelvic tumors and abscesses of variable extent, or it may be identified as frozen pelvis, attributable to the disease's insidious progression. • Central Nervous System disease – Focal neurological deficits and/or indicators of persistent meningitis.
DIAGNOSTIC TESTS AND INTERPRETATION Laboratory
• A significant level of suspicion arises when space-occupying lesions are associated with pus-draining sinus development and involvement of soft tissue or bone.
• Examine the bandage concealing a draining sinus for sulfur granules. • Collect the specimen prior to commencing any antimicrobial treatment.
Preliminary laboratory examinations
• Identification of filamentous, Gram-positive, non-acid-fast organisms in sulfur granules (slide examination) or in specimens taken from a typically sterile site (not in sputum, bronchial washings, or vaginal secretions
A Gram stain of the specimen exhibits more sensitivity than culturing.
• Swab cultures are not advised.
Anaerobic processing of specimens is essential.
Direct immunofluorescence employing specific antisera targeting actinomycosis drugs exhibits good specificity and sensitivity. It has mostly been utilized in the detection and prevention of diseases associated with intrauterine devices.
Imaging: Preliminary Strategy
CT and MRI are useful in delineating the disease's extent and its interaction with neighboring tissues (2, 3).
The open bronchus sign, characterized by the presence of an aerobronchogram within a mass lesion, strongly indicates lung illness.
• A serrated appearance and total involvement of bones are indicative of bone disease.
• The typical presentation of CNS disease consists of single (actinomycetoma) or several round or irregular multiloculated brain lesions, accompanied by edema and areas of low attenuation.
Pathological
Observations
Detection of macroscopic or microscopic "sulfur granules" in pus and/or tissue samples (excluding tonsils), acquired during fine-needle aspiration or biopsy. Tissue Gram and Giemsa stains will identify the organisms located in the granule's periphery.
Differential Diagnosis: Malignant Neoplasms Nocardiosis, Botryomycosis, Tuberculosis, Histoplasmosis, Blastomycosis, Cryptococcosis
THERAPEUTIC PHARMACEUTICAL
Initial Line
• Administer Penicillin G at a dosage of 10–24 million units per day intravenously (in divided doses every 4–6 hours) for a duration of 2–6 weeks, thereafter transitioning to Penicillin V at 2–4 grams per day orally for 6–12 months, or • Administer Ampicillin at a dosage of 50 mg/kg per day intravenously for 2–6 weeks, followed by Amoxicillin at 1.5 grams per day orally for 6–12 months
The duration of treatment is contingent upon the severity of the disease and the clinical response. Benign instances of cervicofacial illness may be managed solely with oral antibiotics.
Second Line • Tetracycline (minocycline) • Erythromycin (alternative for patients with allergies or during pregnancy) • Clindamycin SURGERY/OTHER PROCEDURES
Antibiotic therapy may require adjunctive treatment with surgical procedures including abscess drainage, fibrotic tissue excision, and marsupialization of persistent sinus tracts.
CONTINUED MANAGEMENT SUBSEQUENT SUGGESTIONS
• Highlight the necessity for adherence to long-term pharmacotherapy. • Monitor for signs of medication toxicity.
OUTLOOK
Typically, there is an outstanding response to antibiotics, with no resistance shown in Actinomyces (5). In the event of failure, there is a significant likelihood of an undrained abscess or a resistant bacterial copathogen.
COMPLICATIONS
• Disseminated actinomycosis • Bowel obstruction resulting from severe abdominal/pelvic actinomycosis
FUNDAMENTAL DESCRIPTION
A persistent, slow-progressing, purulent, tissue-destructive infection characterized by the growth of lumps and sinuses, typically affecting the head and neck, but capable of influencing other regions such as the thorax and abdomen.
EPIDEMIOLOGY
Incidence • The documented incidence in the general population is approximately 1:300,000 in the United States and around 1:100,000 in Europe. • Infection manifests across all age groups, with a peak incidence during the middle decades of life. • The male-to-female ratio is 3:1.
RISK FACTORS: • Inadequate oral hygiene, dental interventions, oral surgical procedures, and
psychological injury
• Intrauterine contraceptive devices (all varieties; heightened risk if retained for over 2 years)
• Abdominal surgery, intra-abdominal inflammatory conditions (diverticulitis, appendicitis), foreign objects
Actinomycosis has been documented in contexts of malnutrition and immunodeficiency, including HIV infection, chronic granulomatous illness, and prolonged steroid usage.
Actinomycosis has been documented in patients with infected osteoradionecrosis and bisphosphonate-related mandibular osteonecrosis.
GENERAL PREVENTION
• Maintain optimal oral hygiene, including the elimination of dental plaque.
The identification of Gupta bodies or Actinomyces-like organisms (ALOs) in Papanicolaou cervicovaginal smears may assist in averting the progression of advanced pelvic disease in women with prolonged use of intrauterine contraceptive devices and symptoms indicative of early pelvic actinomycosis, including pain, abnormal bleeding, or unusual discharge. It is advised to remove the intrauterine device and administer a 2- to 3-week regimen of antibiotics in these instances.
• Patient isolation is unnecessary.
PATHOPHYSIOLOGY
Humans serve as the natural reservoir for actinomycosis pathogens.
The organisms often develop as saprophytes in the oral cavity, primarily within dental plaque and tonsillar crypts.
• Transmission likely happens through direct touch between individuals.
• The extraction of teeth or other trauma to the oral mucosa may trigger a localized infection caused by Actinomyces species.
The germs are likely aspirated and may occasionally result in lung actinomycosis.
• The majority of abdominal actinomycosis cases start in the appendix.
• While the precise incubation period remains undetermined, diagnosis typically occurs after extended durations. While an acute variant has been identified, chronic illness constitutes the predominant majority of patients.
• The disruption of the mucosal barrier appears essential for the first onset of the illness. It subsequently disseminates contiguously and/or hematogenously. Aspiration or contiguous dissemination from the cervical region results in pulmonary involvement. Foreign bodies and/or intestinal perforation resulting from appendicitis or diverticulitis contribute to the pathological processes in abdominal and pelvic diseases.
• Depending on the specific anatomical region involved, Oral/cervicofacial, thoracic, abdominal, pelvic, central nervous system (CNS), and disseminated forms of the disease are acknowledged. Muscle and bone involvement is owing to direct extension from surrounding tissue infection or, less commonly, as a result of trauma or infection dissemination.
ETIOLOGY
• Actinomyces are microaerophilic or anaerobic, filamentous, branching, Gram-positive, non-acid-fast bacilli.
• A. israelii is the most prevalent species of Actinomyces discovered in the pus and tissues of individuals afflicted with actinomycosis.
• A. naeslundii, A. meyeri, A. odontolyticus, and Propionibacterium propionica (Arachnia propionica) have been documented as causative agents of human actinomycosis.
• A. viscosus has been identified as a significant factor to the pathogenesis of periodontal disease. • Actinomyces are commensals of the oral cavity and female vaginal system. In most instances of actinomycosis, meticulous cultures produce polymicrobial isolates, predominantly comprising anaerobic constituents of the normal oral flora. These may function as copathogens in the pathological process.
DIAGNOSTIC HISTORY
• Discomfort, vaginal secretion, and/or hemorrhage (pelvic pathology) • Cephalalgia, localized neurological manifestations
• Symptoms are contingent upon the severity of the lesions and the affected organ/system. • Potential manifestations include pain, low-grade fever, and weight loss.
• Trismus (oral/cervicofacial condition) • Chest discomfort, cough (productive or non-productive), progressively worsening shortness of breath (thoracic condition) • Abdominal pain, alteration in bowel habits (abdominal condition)
PHYSICAL EXAM
The characteristic feature of the disease is the development of space-occupying lesions of diverse sizes, exhibiting variable levels of suppuration and/or fibrosis.
– Infiltration into neighboring tissues may transpire, along with outflow to nearby cavities or the skin through sinus development. Sinus conditions may be self-limiting and recurring pus typically contains yellowish "sulfur granules," observable both macroscopically and microscopically.
• Cervicofacial/oral pathology – The perimandibular area is predominantly affected; however, all regions of the head, neck, and oral cavity may be implicated, encompassing soft tissues, bones, salivary glands, thyroid, eyes (postoperative canaliculitis and endophthalmitis), and ears (chronic, myringotomy-resistant otitis media).
– The superficial skin may exhibit a purple, red, or bluish hue. • Thoracic disease – Arises from aspiration or, less commonly, contiguous spread from the cervical region. Indicators suggest a space-occupying lesion and/or pneumonitis, with pleural involvement (thickening, effusion, empyema) observed in over 50% of patients.
– The existence of several cavities and the engagement of the chest wall (including soft tissues and bones with sinus development) corroborate the diagnosis.
Mediastinal involvement, primarily affecting heart tissues, and spinal involvement may occur.
• Abdominal pathology – Symptoms include the presence of a firm or hard mass lesion, typically located in the right iliac fossa, sometimes subsequent to ruptured appendicitis.
- Disease of the left iliac fossa is a consequence of diverticulitis.
Perirectal or perianal illness manifests as chronic recurrent abscesses and the establishment of sinuses or fistulas in the pertinent area are noted. Peritonitis is uncommon.
• Pelvic disease – Manifestations include pelvic tumors and abscesses of variable extent, or it may be identified as frozen pelvis, attributable to the disease's insidious progression. • Central Nervous System disease – Focal neurological deficits and/or indicators of persistent meningitis.
DIAGNOSTIC TESTS AND INTERPRETATION Laboratory
• A significant level of suspicion arises when space-occupying lesions are associated with pus-draining sinus development and involvement of soft tissue or bone.
• Examine the bandage concealing a draining sinus for sulfur granules. • Collect the specimen prior to commencing any antimicrobial treatment.
Preliminary laboratory examinations
• Identification of filamentous, Gram-positive, non-acid-fast organisms in sulfur granules (slide examination) or in specimens taken from a typically sterile site (not in sputum, bronchial washings, or vaginal secretions
A Gram stain of the specimen exhibits more sensitivity than culturing.
• Swab cultures are not advised.
Anaerobic processing of specimens is essential.
Direct immunofluorescence employing specific antisera targeting actinomycosis drugs exhibits good specificity and sensitivity. It has mostly been utilized in the detection and prevention of diseases associated with intrauterine devices.
Imaging: Preliminary Strategy
CT and MRI are useful in delineating the disease's extent and its interaction with neighboring tissues (2, 3).
The open bronchus sign, characterized by the presence of an aerobronchogram within a mass lesion, strongly indicates lung illness.
• A serrated appearance and total involvement of bones are indicative of bone disease.
• The typical presentation of CNS disease consists of single (actinomycetoma) or several round or irregular multiloculated brain lesions, accompanied by edema and areas of low attenuation.
Pathological
Observations
Detection of macroscopic or microscopic "sulfur granules" in pus and/or tissue samples (excluding tonsils), acquired during fine-needle aspiration or biopsy. Tissue Gram and Giemsa stains will identify the organisms located in the granule's periphery.
Differential Diagnosis: Malignant Neoplasms Nocardiosis, Botryomycosis, Tuberculosis, Histoplasmosis, Blastomycosis, Cryptococcosis
THERAPEUTIC PHARMACEUTICAL
Initial Line
• Administer Penicillin G at a dosage of 10–24 million units per day intravenously (in divided doses every 4–6 hours) for a duration of 2–6 weeks, thereafter transitioning to Penicillin V at 2–4 grams per day orally for 6–12 months, or • Administer Ampicillin at a dosage of 50 mg/kg per day intravenously for 2–6 weeks, followed by Amoxicillin at 1.5 grams per day orally for 6–12 months
The duration of treatment is contingent upon the severity of the disease and the clinical response. Benign instances of cervicofacial illness may be managed solely with oral antibiotics.
Second Line • Tetracycline (minocycline) • Erythromycin (alternative for patients with allergies or during pregnancy) • Clindamycin SURGERY/OTHER PROCEDURES
Antibiotic therapy may require adjunctive treatment with surgical procedures including abscess drainage, fibrotic tissue excision, and marsupialization of persistent sinus tracts.
CONTINUED MANAGEMENT SUBSEQUENT SUGGESTIONS
• Highlight the necessity for adherence to long-term pharmacotherapy. • Monitor for signs of medication toxicity.
OUTLOOK
Typically, there is an outstanding response to antibiotics, with no resistance shown in Actinomyces (5). In the event of failure, there is a significant likelihood of an undrained abscess or a resistant bacterial copathogen.
COMPLICATIONS
• Disseminated actinomycosis • Bowel obstruction resulting from severe abdominal/pelvic actinomycosis
- Published on
Infectious Disease - Acne Vulgaris
FUNDAMENTAL DESCRIPTION
Acne vulgaris is a persistent inflammatory condition of the sebaceous follicles, which are specialized pilosebaceous units.
EPIDEMIOLOGY • Acne vulgaris is among the most prevalent dermatological conditions, impacting about 85% of individuals at some point from age 15 to the 40s. • The average age of onset is 24. • It constitutes up to 2 million outpatient consultations for patients aged 15–19 years.
RISK FACTORS • A known risk factor is the hyperresponsiveness of sebaceous cells and keratinocytes to androgenic hormones. • Androgenic hormones likely play a role in the setting of puberty and women with raised levels of testosterone, dehydroepiandrosterone sulphate, or androstenedione.
GENERAL PREVENTION • Refrain from extensive exposure to skin irritants. • Upholding fundamental hygienic standards.
PATHOPHYSIOLOGY
Inflammatory alterations affecting the sebaceous follicles result in the buildup of lipid-rich sebum and bacterial proliferation.
· CAUSES
Propionibacterium acnes is an anaerobic, Gram-positive bacterium that inhabits the androgen-stimulated sebaceous follicle and is a typical component of the cutaneous microbiota. Typically characterized by a minimal bacterial load.
• Sebaceous follicles secrete sebum, a lipid-rich product from sebaceous glands that serves as a nutrient-rich medium for P. acnes. • The initial catalyst seems to be an overproliferation of P. acnes, leading to inflammation, follicular rupture, and the propagation of the inflammatory response into the adjacent dermis. This culminates in the development of papules, pustules, and nodules.
DIAGNOSTIC HISTORY
• Characterized by the existence of closed (whitehead) or open (blackhead) comedones. • In more severe instances, comedones may experience inflammatory alterations, potentially resulting in painful nodules, pustules, or cellulitis.
• Confined to regions of the body with the highest concentration of sebaceous glands: face, neck, chest, upper back, and upper arms.
PHYSICAL EXAM
· • A variety of features may be observed, ranging from noninflamed comedones (either open or closed) to active nodules and/or pustules.
• The presence of scarring typically signifies a more severe form of acne vulgaris. • Based on the location and intensity of inflammation, acne can be categorized as mild, moderate, or severe.
– Mild often encompasses noninflammatory comedones.
- Moderate presents with a heightened quantity of inflammatory pustules and papules impacting a broader skin surface area.
Severe acne is characterized by big, painful nodules and may result in scar formation.
THERAPY
• Contingent upon the degree of acne. Topical treatment can be effective for mild to moderate acne.
The primary components of treatment consist of antibacterial medicines, anti-inflammatory medications, and retinoids for the differentiation of follicular keratinocytes.
· PHARMACEUTICALS
Retinoids
• Retinoids diminish the size and secretion of sebaceous glands. • Topical treatments are most efficacious in preventing additional comedone formation.
• Certain topical retinoids, including tazarotene, may induce significant irritation.
• In cases of severe acne, particularly when scarring is anticipated, systemic retinoid therapy with oral isotretinoin is recommended.
Isotretinoin has demonstrated anti-inflammatory properties and suppresses the proliferation of P. acnes, contributing to its efficacy.
• Typical adverse effects of oral retinoids Isotretinoin may cause birth abnormalities and hypertriglyceridemia. Young women should get counseling regarding the utilization of two contraceptive methods while undergoing oral retinoid treatment.
Connections between isotretinoin and depression/suicide have been documented.
Antimicrobials
• Specified whether an inflammatory component is observed.
Benzoyl peroxide is an effective first-line bactericidal agent having a rapid onset of action.
The incorporation of topical antimicrobials is efficacious when utilized alongside benzoyl peroxide or retinoids.
Topical antimicrobials utilized in isolation often result in elevated resistance levels and treatment failure.
• In cases of severe acne, oral antimicrobials are warranted. • Frequently utilized medications exhibiting efficacy against P. acnes encompass tetracyclines (minocycline, tetracycline, doxycycline), bactrim, erythromycin, and clindamycin. • An increase in resistance has been seen, with over 50% of P. acnes exhibiting complete resistance to at least one antimicrobial agent. The predominant resistance is shown in the following order: erythromycin, followed by clindamycin, and then tetracycline.
Patient education and medication adherence are essential, and drug resistance must be taken into account in a deteriorating patient.
• An additional reason of clinical failure is the proliferation of Gram-negative bacteria.
Gram-negative bacteria.
· Considerations During Pregnancy
Oral isotretinoin is strongly teratogenic.
· SUPPLEMENTARY THERAPY
Supplementary Treatments
In the context of hyperandrogenism, medicines like spironolactone are effective in inhibiting the excessive development of androgen-sensitive sebaceous glands.
• Oral contraceptives have been demonstrated to decrease the incidence of acne. • For significant inflammatory alterations, intralesional corticosteroid administration may be employed.
· COMPLEMENTARY AND ALTERNATIVE THERAPIES
The roles of chemical and physical microabrasion and laser treatment remain undefined.
FUNDAMENTAL DESCRIPTION
Acne vulgaris is a persistent inflammatory condition of the sebaceous follicles, which are specialized pilosebaceous units.
EPIDEMIOLOGY • Acne vulgaris is among the most prevalent dermatological conditions, impacting about 85% of individuals at some point from age 15 to the 40s. • The average age of onset is 24. • It constitutes up to 2 million outpatient consultations for patients aged 15–19 years.
RISK FACTORS • A known risk factor is the hyperresponsiveness of sebaceous cells and keratinocytes to androgenic hormones. • Androgenic hormones likely play a role in the setting of puberty and women with raised levels of testosterone, dehydroepiandrosterone sulphate, or androstenedione.
GENERAL PREVENTION • Refrain from extensive exposure to skin irritants. • Upholding fundamental hygienic standards.
PATHOPHYSIOLOGY
Inflammatory alterations affecting the sebaceous follicles result in the buildup of lipid-rich sebum and bacterial proliferation.
· CAUSES
Propionibacterium acnes is an anaerobic, Gram-positive bacterium that inhabits the androgen-stimulated sebaceous follicle and is a typical component of the cutaneous microbiota. Typically characterized by a minimal bacterial load.
• Sebaceous follicles secrete sebum, a lipid-rich product from sebaceous glands that serves as a nutrient-rich medium for P. acnes. • The initial catalyst seems to be an overproliferation of P. acnes, leading to inflammation, follicular rupture, and the propagation of the inflammatory response into the adjacent dermis. This culminates in the development of papules, pustules, and nodules.
DIAGNOSTIC HISTORY
• Characterized by the existence of closed (whitehead) or open (blackhead) comedones. • In more severe instances, comedones may experience inflammatory alterations, potentially resulting in painful nodules, pustules, or cellulitis.
• Confined to regions of the body with the highest concentration of sebaceous glands: face, neck, chest, upper back, and upper arms.
PHYSICAL EXAM
· • A variety of features may be observed, ranging from noninflamed comedones (either open or closed) to active nodules and/or pustules.
• The presence of scarring typically signifies a more severe form of acne vulgaris. • Based on the location and intensity of inflammation, acne can be categorized as mild, moderate, or severe.
– Mild often encompasses noninflammatory comedones.
- Moderate presents with a heightened quantity of inflammatory pustules and papules impacting a broader skin surface area.
Severe acne is characterized by big, painful nodules and may result in scar formation.
THERAPY
• Contingent upon the degree of acne. Topical treatment can be effective for mild to moderate acne.
The primary components of treatment consist of antibacterial medicines, anti-inflammatory medications, and retinoids for the differentiation of follicular keratinocytes.
· PHARMACEUTICALS
Retinoids
• Retinoids diminish the size and secretion of sebaceous glands. • Topical treatments are most efficacious in preventing additional comedone formation.
• Certain topical retinoids, including tazarotene, may induce significant irritation.
• In cases of severe acne, particularly when scarring is anticipated, systemic retinoid therapy with oral isotretinoin is recommended.
Isotretinoin has demonstrated anti-inflammatory properties and suppresses the proliferation of P. acnes, contributing to its efficacy.
• Typical adverse effects of oral retinoids Isotretinoin may cause birth abnormalities and hypertriglyceridemia. Young women should get counseling regarding the utilization of two contraceptive methods while undergoing oral retinoid treatment.
Connections between isotretinoin and depression/suicide have been documented.
Antimicrobials
• Specified whether an inflammatory component is observed.
Benzoyl peroxide is an effective first-line bactericidal agent having a rapid onset of action.
The incorporation of topical antimicrobials is efficacious when utilized alongside benzoyl peroxide or retinoids.
Topical antimicrobials utilized in isolation often result in elevated resistance levels and treatment failure.
• In cases of severe acne, oral antimicrobials are warranted. • Frequently utilized medications exhibiting efficacy against P. acnes encompass tetracyclines (minocycline, tetracycline, doxycycline), bactrim, erythromycin, and clindamycin. • An increase in resistance has been seen, with over 50% of P. acnes exhibiting complete resistance to at least one antimicrobial agent. The predominant resistance is shown in the following order: erythromycin, followed by clindamycin, and then tetracycline.
Patient education and medication adherence are essential, and drug resistance must be taken into account in a deteriorating patient.
• An additional reason of clinical failure is the proliferation of Gram-negative bacteria.
Gram-negative bacteria.
· Considerations During Pregnancy
Oral isotretinoin is strongly teratogenic.
· SUPPLEMENTARY THERAPY
Supplementary Treatments
In the context of hyperandrogenism, medicines like spironolactone are effective in inhibiting the excessive development of androgen-sensitive sebaceous glands.
• Oral contraceptives have been demonstrated to decrease the incidence of acne. • For significant inflammatory alterations, intralesional corticosteroid administration may be employed.
· COMPLEMENTARY AND ALTERNATIVE THERAPIES
The roles of chemical and physical microabrasion and laser treatment remain undefined.
